中国银屑病诊疗指南（2023版）

doi:10.35541/cjd.20220839

Abstract

Abstract: 【Abstract】 Psoriasis is an immune-mediated chronic, recurrent, inflammatory, systemic disease induced by the interaction between the individual and environment. Psoriasis is a non-communicable disease, its typical clinical manifestations are locally or widely distributed scaly erythema or plaques. The etiology of psoriasis involves heredity, immunity, environment, and other factors. Until now, psoriasis is still an incurable disease. Choosing appropriate drugs and regimens is very important for patients with psoriasis to control the condition, reduce comorbidities, maintain long-term efficacy, and comprehensively improve the quality of life. To standardize the diagnosis and treatment procedure of psoriasis, improve treatment effectiveness, and minimize adverse reactions, the Committee on Psoriasis of Chinese Society of Dermatology formulated this guideline based on the "Guideline for the diagnosis and treatment of psoriasis in China （2018 complete edition）" and according to the current situation in China, with some contents supplemented and revised in this guideline. Because latest research achievements in traditional Chinese medicine for the diagnosis and treatment of psoriasis were combined, this guideline was also an integrated Chinese and Western medicine guideline for the diagnosis and treatment of psoriasis. Considering the complexity of psoriasis, the treatment regimens should be decided according to patients′ individual situation. Topical treatment is commonly recommended for patients with mild psoriasis, systemic treatment can be chosen for those with moderate to severe psoriasis, and biological agents or small-molecule drugs can be selected for those with poor response to traditional systemic treatment.

Key words: Psoriasis, Diagnosis, Treatment, Guidelines

Committee on Psoriasis, Chinese Society of Dermatology. Guideline for the diagnosis and treatment of psoriasis in China （2023 edition）[J]. Chinese Journal of Dermatology, 2023, 56(7): 573-625.doi:10.35541/cjd.20220839

References ［393］

［1］	张学军, 郑捷. 皮肤性病学［M］. 9版. 北京: 人民卫生出版社, 2018:133.
［2］	中华医学会, 中华医学会杂志社, 中华医学会皮肤性病学分会, 等. 银屑病基层诊疗指南（2022年）［J］. 中华全科医师杂志, 2022,21（8）:705⁃714. doi: 10.3760/cma.j.cn114798⁃20220214⁃ 00098.
［3］	全国银屑病流行调查组. 全国1984年银屑病流行调查报告［J］. 中华皮肤科杂志, 1986,19（5）:253⁃261.
［4］	丁晓岚, 王婷琳, 沈佚葳, 等. 中国六省市银屑病流行病学调查［J］. 中国皮肤性病学杂志, 2010,24（7）:598⁃601.
［5］	Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence［J］. J Invest Dermatol, 2013,133（2）:377⁃385. doi: 10.1038/jid.2012. 339.
［6］	Miller IM, Ellervik C, Yazdanyar S, et al. Meta⁃analysis of psoriasis, cardiovascular disease, and associated risk factors［J］. J Am Acad Dermatol, 2013,69（6）:1014⁃1024. doi: 10.1016/j.jaad.2013.06.053.
［7］	Yang Q, Qu L, Tian H, et al. Prevalence and characteristics of psoriatic arthritis in Chinese patients with psoriasis［J］. J Eur Acad Dermatol Venereol, 2011,25（12）:1409⁃1414. doi: 10.1111/ j.1468⁃3083.2011.03985.x.
［8］	Mease Pj, Ps H. Atlas of psoriatic arthritis［M］. London: Springer, 2008.
［9］	Ghoreschi K, Balato A, Enerbäck C, et al. Therapeutics targeting the IL⁃23 and IL⁃17 pathway in psoriasis［J］. Lancet, 2021,397（10275）:754⁃766. doi: 10.1016/S0140⁃6736（21）00184⁃7.
［10］	Zhang X, Wang H, Te⁃Shao H, et al. The genetic epidemiology of psoriasis vulgaris in Chinese Han［J］. Int J Dermatol, 2002,41（10）:663⁃669. doi: 10.1046/j.1365⁃4362.2002.01596.x.
［11］	Ayala⁃Fontánez N, Soler DC, McCormick TS. Current knowledge on psoriasis and autoimmune diseases［J］. Psoriasis （Auckl）, 2016,6:7⁃32. doi: 10.2147/PTT.S64950.
［12］	Griffiths C, Armstrong AW, Gudjonsson JE, et al. Psoriasis［J］. Lancet, 2021,397（10281）:1301⁃1315. doi: 10.1016/S0140⁃6736（20）32549⁃6.
［13］	Nair RP, Stuart PE, Nistor I, et al. Sequence and haplotype analysis supports HLA⁃C as the psoriasis susceptibility 1 gene［J］. Am J Hum Genet, 2006,78（5）:827⁃851. doi: 10.1086/503821.
［14］	Zhang XJ, Yan KL, Wang ZM, et al. Polymorphisms in interleukin⁃15 gene on chromosome 4q31.2 are associated with psoriasis vulgaris in Chinese population［J］. J Invest Dermatol, 2007,127（11）:2544⁃2551. doi: 10.1038/sj.jid.5700896.
［15］	Zhang XJ, Huang W, Yang S, et al. Psoriasis genome⁃wide association study identifies susceptibility variants within LCE gene cluster at 1q21［J］. Nat Genet, 2009,41（2）:205⁃210. doi: 10.1038/ng.310.
［16］	Tang H, Jin X, Li Y, et al. A large⁃scale screen for coding variants predisposing to psoriasis［J］. Nat Genet, 2014,46（1）:45⁃50. doi: 10.1038/ng.2827.
［17］	Singh S, Pradhan D, Puri P, et al. Genomic alterations driving psoriasis pathogenesis［J］. Gene, 2019,683:61⁃71. doi: 10.1016/j.gene.2018.09.042.
［18］	Zhang Z, Ma Y, Zhang Z, et al. Identification of two loci associated with generalized pustular psoriasis［J］. J Invest Dermatol, 2015,135（8）:2132⁃2134. doi: 10.1038/jid.2015.111.
［19］	Haroon M, Winchester R, Giles JT, et al. Certain class I HLA alleles and haplotypes implicated in susceptibility play a role in determining specific features of the psoriatic arthritis phenotype［J］. Ann Rheum Dis, 2016,75（1）:155⁃162. doi: 10.1136/annrheumdis⁃2014⁃205461.
［20］	Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis［J］. Lancet, 2007,370（9583）:263⁃271. doi: 10.1016/S0140⁃6736（07）61128⁃3.
［21］	Winchell SA, Watts RA. Relaxation therapies in the treatment of psoriasis and possible pathophysiologic mechanisms［J］. J Am Acad Dermatol, 1988,18（1 Pt 1）:101⁃104. doi: 10.1016/s0190⁃9622（88）70015⁃8.
［22］	Mohla G, Brodell RT. Koebner phenomenon in psoriasis. A common response to skin trauma［J］. Postgrad Med, 1999,106（3）:39⁃40. doi: 10.3810/pgm.1999.09.693.
［23］	Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies［J］. J Allergy Clin Immunol, 2017,140（3）:645⁃653. doi: 10.1016/j.jaci.2017.07.004.
［24］	Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review［J］. JAMA, 2020,323（19）:1945⁃1960. doi: 10.1001/jama.2020.4006.
［25］	Chiricozzi A, Guttman⁃Yassky E, Suárez⁃Fariñas M, et al. Integrative responses to IL⁃17 and TNF⁃α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis［J］. J Invest Dermatol, 2011,131（3）:677⁃687. doi: 10.1038/jid.2010.340.
［26］	Kryczek I, Bruce AT, Gudjonsson JE, et al. Induction of IL⁃17+ T cell trafficking and development by IFN⁃gamma: mechanism and pathological relevance in psoriasis［J］. J Immunol, 2008,181（7）:4733⁃4741. doi: 10.4049/jimmunol.181.7.4733.
［27］	de Jesús⁃Gil C, Ruiz⁃Romeu E, Ferran M, et al. IL⁃15 and IL⁃23 synergize to trigger Th17 response by CLA+ T cells in psoriasis［J］. Exp Dermatol, 2020,29（7）:630⁃638. doi: 10.1111/exd.14113.
［28］	Shi X, Jin L, Dang E, et al. IL⁃17A upregulates keratin 17 expression in keratinocytes through STAT1⁃ and STAT3⁃dependent mechanisms［J］. J Invest Dermatol, 2011,131（12）:2401⁃2408. doi: 10.1038/jid.2011.222.
［29］	Jin L, Wang G. Keratin 17: a critical player in the pathogenesis of psoriasis［J］. Med Res Rev, 2014,34（2）:438⁃454. doi: 10. 1002/med.21291.
［30］	Klein B, Treudler R, Simon JC. JAK⁃inhibitors in dermatology ⁃ small molecules, big impact? Overview of the mechanism of action, previous study results and potential adverse effects［J］. J Dtsch Dermatol Ges, 2022,20（1）:19⁃24. doi: 10.1111/ddg.14668.
［31］	Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase⁃4 inhibitor, demonstrates anti⁃inflammatory activity in vitro and in a model of psoriasis［J］. Br J Pharmacol, 2010,159（4）:842⁃855. doi: 10.1111/j.1476⁃5381.2009.00559.x.
［32］	Zheng M, Jullien D, Eyerich K. The prevalence and disease characteristics of generalized pustular psoriasis［J］. Am J Clin Dermatol, 2022,23（Suppl 1）:5⁃12. doi: 10.1007/s40257⁃021⁃00664⁃x.
［33］	Naldi L, Svensson A, Diepgen T, et al. Randomized clinical trials for psoriasis 1977-2000: the EDEN survey［J］. J Invest Dermatol, 2003,120（5）:738⁃741. doi: 10.1046/j.1523⁃1747.2003. 12145.x.
［34］	Nast A, Altenburg A, Augustin M, et al. German S3⁃Guideline on the treatment of psoriasis vulgaris, adapted from EuroGuiDerm ⁃ part 1: treatment goals and treatment recommendations［J］. J Dtsch Dermatol Ges, 2021,19（6）:934⁃150. doi: 10.1111/ddg.14508.
［35］	Nast A, Altenburg A, Augustin M, et al. German S3⁃Guideline on the treatment of psoriasis vulgaris, adapted from EuroGuiDerm ⁃ part 2: treatment monitoring and specific clinical or comorbid situations［J］. J Dtsch Dermatol Ges, 2021,19（7）:1092⁃1115. doi: 10.1111/ddg.14507.
［36］	Nast A, Smith C, Spuls PI, et al. EuroGuiDerm Guideline on the systemic treatment of psoriasis vulgaris ⁃ part 1: treatment and monitoring recommendations［J］. J Eur Acad Dermatol Venereol, 2020,34（11）:2461⁃2498. doi: 10.1111/jdv.16915.
［37］	Nast A, Smith C, Spuls PI, et al. EuroGuiDerm Guideline on the systemic treatment of psoriasis vulgaris ⁃ part 2: specific clinical and comorbid situations［J］. J Eur Acad Dermatol Venereol, 2021,35（2）:281⁃317. doi: 10.1111/jdv.16926.
［38］	Smith CH, Yiu Z, Bale T, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update［J］. Br J Dermatol, 2020,183（4）:628⁃637. doi: 10.1111/bjd.19039.
［39］	中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会, 中国中西医结合学会皮肤性病专业委员会. 中国银屑病生物制剂治疗指南（2021）［J］. 中华皮肤科杂志, 2021,54（12）:1033⁃1047. doi: 10.35541/cjd.20210643.
［40］	Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study［J］. Arthritis Rheum, 2006,54（8）:2665⁃2673. doi: 10.1002/art.21972.
［41］	Golińska J, Sar⁃Pomian M, Rudnicka L. Dermoscopic features of psoriasis of the skin, scalp and nails ⁃ a systematic review［J］. J Eur Acad Dermatol Venereol, 2019,33（4）:648⁃660. doi: 10. 1111/jdv.15344.
［42］	Golińska J, Sar⁃Pomian M, Rudnicka L. Dermoscopy of plaque psoriasis differs with plaque location, its duration, and patient′s sex［J］. Skin Res Technol, 2021,27（2）:217⁃226. doi: 10.1111/srt.12933.
［43］	徐晨琛, 陈典, 刘洁, 等. 皮肤镜在头皮银屑病和脂溢性皮炎诊断及鉴别诊断中的应用［J］. 中华医学杂志, 2014,94（44）:3467⁃3470. doi: 10.3760/cma.j.issn.0376⁃2491.2014.44.004.
［44］	Micali G, Nardone B, Scuderi A, et al. Videodermatoscopy enhances the diagnostic capability of palmar and/or plantar psoriasis［J］. Am J Clin Dermatol, 2008,9（2）:119⁃122. doi: 10. 2165/00128071⁃200809020⁃00005.
［45］	Wanniang N, Navya A, Pai V, et al. Comparative study of clinical and dermoscopic features in nail psoriasis［J］. Indian Dermatol Online J, 2020,11（1）:35⁃40. doi: 10.4103/idoj.IDOJ_51_19.
［46］	González S, Rajadhyaksha M, Rubinstein G, et al. Characterization of psoriasis in vivo by reflectance confocal microscopy［J］. J Med, 1999,30（5⁃6）:337⁃356.
［47］	Ardigo M, Cota C, Berardesca E, et al. Concordance between in vivo reflectance confocal microscopy and histology in the evaluation of plaque psoriasis［J］. J Eur Acad Dermatol Venereol, 2009,23（6）:660⁃667. doi: 10.1111/j.1468⁃3083.2009.03134.x.
［48］	Batani A, Brănișteanu DE, Ilie MA, et al. Assessment of dermal papillary and microvascular parameters in psoriasis vulgaris using in vivo reflectance confocal microscopy［J］. Exp Ther Med, 2018,15（2）:1241⁃1246. doi: 10.3892/etm.2017.5542.
［49］	刘华绪, 林燕, 单晓峰, 等. 反射式共聚焦激光扫描显微镜在银屑病诊疗中的应用［J］. 中国麻风皮肤病杂志, 2011,27（7）:488⁃491. doi: 10.3969/j.issn.1009⁃1157.2011.07.019.
［50］	Cucoş M, Crişan M, Lenghel M, et al. Conventional ultrasonography and sonoelastography in the assessment of plaque psoriasis under topical corticosteroid treatment ⁃ work in progress［J］. Med Ultrason, 2014,16（2）:107⁃113. doi: 10.11152/mu.2013.2066.162.mc1mc2.
［51］	Grajdeanu IA, Statescu L, Vata D, et al. Imaging techniques in the diagnosis and monitoring of psoriasis［J］. Exp Ther Med, 2019,18（6）:4974⁃4980. doi: 10.3892/etm.2019.7957.
［52］	宋坪, 颜志芳, 王丽昀, 等. 高分辨率超声检测斑块状银屑病表皮真皮厚度［J］. 中国临床医学影像杂志, 2009,20（4）:294⁃295. doi: 10.3969/j.issn.1008⁃1062.2009.04.022.
［53］	Gisondi P, Idolazzi L, Girolomoni G. Ultrasonography reveals nail thickening in patients with chronic plaque psoriasis［J］. Arch Dermatol Res, 2012,304（9）:727⁃732. doi: 10.1007/s00403⁃012⁃1274⁃9.
［54］	Marina ME, Solomon C, Bolboaca SD, et al. High⁃frequency sonography in the evaluation of nail psoriasis［J］. Med Ultrason, 2016,18（3）:312⁃317. doi: 10.11152/mu.2013.2066.183.hgh.
［55］	Gutierrez M, Draghessi A, Bertolazzi C, et al. Ultrasound in psoriatic arthritis. Can it facilitate a best routine practice in the diagnosis and management of psoriatic arthritis?［J］. Clin Rheumatol, 2015,34（11）:1847⁃1855. doi: 10.1007/s10067⁃015⁃3053⁃4.
［56］	Girolimetto N, Macchioni P, Tinazzi I, et al. Ultrasonographic evidence of predominance of acute extracapsular and chronic intrasynovial patterns in 100 cases of psoriatic hand dactylitis［J］. J Rheumatol, 2020,47（2）:227⁃233. doi: 10.3899/jrheum. 190046.
［57］	丁丽, 李薇. 高频肌骨超声在银屑病性关节炎诊断中的应用［J］. 中国皮肤性病学杂志, 2022,36（5）:603⁃606,610. doi: 10.13735/j.cjdv.1001⁃7089.202006045.
［58］	王晶, 庞丽娜, 宋宏萍. 超声、X线及MRI检出银屑病关节炎踝关节病变的对比研究［J］. 临床超声医学杂志, 2018,20（1）:19⁃21. doi: 10.3969/j.issn.1008⁃6978.2018.01.007.
［59］	《中国关节病型银屑病诊疗共识（2020）》编写委员会专家组. 中国关节病型银屑病诊疗共识（2020）［J］. 中华皮肤科杂志, 2020,53（8）:585⁃595. doi: 10.35541/cjd.20200369.
［60］	张跃, 胡颖. 关节病型银屑病的临床特点及影像学表现［J］. 中国CT和MRI杂志, 2017,15（5）:36⁃38. doi: 10.3969/j.issn. 1672⁃5131.2017.05.011.
［61］	Finzel S, Englbrecht M, Engelke K, et al. A comparative study of periarticular bone lesions in rheumatoid arthritis and psoriatic arthritis［J］. Ann Rheum Dis, 2011,70（1）:122⁃127. doi: 10.1136/ard.2010.132423.
［62］	Finzel S, Sahinbegovic E, Kocijan R, et al. Inflammatory bone spur formation in psoriatic arthritis is different from bone spur formation in hand osteoarthritis［J］. Arthritis Rheumatol, 2014,66（11）:2968⁃2975. doi: 10.1002/art.38794.
［63］	Felbo SK, Terslev L, Østergaard M. Imaging in peripheral and axial psoriatic arthritis: contributions to diagnosis, follow⁃up, prognosis and knowledge of pathogenesis［J］. Clin Exp Rheumatol, 2018,36 Suppl 114（5）:24⁃34.
［64］	Ostergaard M, McQueen F, Wiell C, et al. The OMERACT psoriatic arthritis magnetic resonance imaging scoring system （PsAMRIS）: definitions of key pathologies, suggested MRI sequences, and preliminary scoring system for PsA Hands［J］. J Rheumatol, 2009,36（8）:1816⁃1824. doi: 10.3899/jrheum.090352.
［65］	Mathew AJ, Bird P, Gupta A, et al. Magnetic resonance imaging （MRI） of feet demonstrates subclinical inflammatory joint disease in cutaneous psoriasis patients without clinical arthritis［J］. Clin Rheumatol, 2018,37（2）:383⁃388. doi: 10.1007/s10067⁃017⁃3895⁃z.
［66］	Maldonado⁃Ficco H, Sheane BJ, Thavaneswaran A, et al. Magnetic resonance imaging in psoriatic arthritis: a descriptive study of indications, features and effect on treatment change［J］. J Clin Rheumatol, 2017,23（5）:243⁃245. doi: 10.1097/RHU.000 0000000000558.
［67］	Braga MV, de Oliveira SC, Vasconcelos A, et al. Prevalence of sacroiliitis and acute and structural changes on MRI in patients with psoriatic arthritis［J］. Sci Rep, 2020,10（1）:11580. doi: 10.1038/s41598⁃020⁃68456⁃7.
［68］	Fassio A, Matzneller P, Idolazzi L. Recent advances in imaging for diagnosis, monitoring, and prognosis of psoriatic arthritis［J］. Front Med （Lausanne）, 2020,7:551684. doi: 10.3389/fmed.2020. 551684.
［69］	中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南（2018完整版）［J］. 中华皮肤科杂志, 2019, 52（10）: 667⁃710.doi:10.35541/cjd.20190847.
［70］	Ye F, Gui X, Wu C, et al. Severity evaluation and prognostic factors in erythrodermic psoriasis［J］. Eur J Dermatol, 2018,28（6）:851⁃853. doi: 10.1684/ejd.2018.3437.
［71］	Singh JA, Guyatt G, Ogdie A, et al. Special article: 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis［J］. Arthritis Rheumatol, 2019,71（1）:5⁃32. doi: 10.1002/art.40726.
［72］	Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials［J］. Ann Rheum Dis, 2005,64 Suppl 2（Suppl 2）:ii65⁃68; discussion ii69⁃73. doi: 10.1136/ard.2004.031237.
［73］	Bożek A, Reich A. The reliability of three psoriasis assessment tools: psoriasis area and severity index, body surface area and physician global assessment［J］. Adv Clin Exp Med, 2017,26（5）:851⁃856. doi: 10.17219/acem/69804.
［74］	Finlay AY, Khan GK. Dermatology Life Quality Index （DLQI）⁃⁃a simple practical measure for routine clinical use［J］. Clin Exp Dermatol, 1994,19（3）:210⁃216. doi: 10.1111/j.1365⁃2230.1994.tb01167.x.
［75］	Strober B, Ryan C, van de Kerkhof P, et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council［J］. J Am Acad Dermatol, 2020,82（1）:117⁃122. doi: 10.1016/j.jaad.2019.08.026.
［76］	National Psoriasis Foundation. Stand up against step therapy［EB/OL］. ［2022⁃10⁃21］. http://www.steptherapy.com/.
［77］	Henseler T, Christophers E. Disease concomitance in psoriasis［J］. J Am Acad Dermatol, 1995,32（6）:982⁃986. doi: 10.1016/0190⁃9622（95）91336⁃x.
［78］	Ulrich Mrowietz C K, Annie Gue′Rin. Comorbidity prevalence in psoriasis patients: a meta⁃analysis ［J］. J Am Acad Dermatol, 2010,62（Issue 3）: Supplement 1,AB123.
［79］	Cai J, Cui L, Wang Y, et al. Cardiometabolic comorbidities in patients with psoriasis: focusing on risk, biological therapy, and pathogenesis［J］. Front Pharmacol, 2021,12:774808. doi: 10. 3389/fphar.2021.774808.
［80］	Wu JJ, Poon KY, Channual JC, et al. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis［J］. Arch Dermatol, 2012,148（11）:1244⁃1250. doi: 10.1001/archdermatol.2012.2502.
［81］	Makavos G, Ikonomidis I, Andreadou I, et al. Effects of interleukin 17A inhibition on myocardial deformation and vascular function in psoriasis［J］. Can J Cardiol, 2020,36（1）:100⁃111. doi: 10.1016/j.cjca.2019.06.021.
［82］	Wu JJ, Guérin A, Sundaram M, et al. Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor⁃α inhibitors versus methotrexate［J］. J Am Acad Dermatol, 2017,76（1）:81⁃90. doi: 10.1016/j.jaad.2016.07.042.
［83］	Elnabawi YA, Dey AK, Goyal A, et al. Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study［J］. Cardiovasc Res, 2019,115（4）:721⁃728. doi: 10.1093/cvr/cvz009.
［84］	Choi H, Uceda DE, Dey AK, et al. Treatment of psoriasis with biologic therapy is associated with improvement of coronary artery plaque lipid⁃rich necrotic core: results from a prospective, observational study［J］. Circ Cardiovasc Imaging, 2020,13（9）:e011199. doi: 10.1161/CIRCIMAGING.120.011199.
［85］	Fernández⁃Armenteros JM, Gómez⁃Arbonés X, Buti⁃Soler M, et al. Psoriasis, metabolic syndrome and cardiovascular risk
	factors. A population⁃based study［J］. J Eur Acad Dermatol Venereol, 2019,33（1）:128⁃135. doi: 10.1111/jdv.15159.
［86］	Takeshita J, Wang S, Shin DB, et al. Effect of psoriasis severity on hypertension control: a population⁃based study in the United Kingdom［J］. JAMA Dermatol, 2015,151（2）:161⁃169. doi: 10. 1001/jamadermatol.2014.2094.
［87］	Chiu HY, Chang WL, Shiu MN, et al. Psoriasis is associated with a greater risk for cardiovascular procedure and surgery in patients with hypertension: a nationwide cohort study［J］. J Dermatol, 2018,45（12）:1381⁃1388. doi: 10.1111/1346⁃8138. 14654.
［88］	Song G, Yoon HY, Yee J, et al. Antihypertensive drug use and psoriasis: a systematic review, meta⁃ and network meta⁃analysis［J］. Br J Clin Pharmacol, 2022,88（3）:933⁃941. doi: 10.1111/bcp.15060.
［89］	Wan MT, Shin DB, Hubbard RA, et al. Psoriasis and the risk of diabetes: a prospective population⁃based cohort study［J］. J Am Acad Dermatol, 2018,78（2）:315⁃322.e1. doi: 10.1016/j.jaad. 2017.10.050.
［90］	Wang H, Wang Z, Rani PL, et al. Identification of PTPN22, ST6GAL1 and JAZF1 as psoriasis risk genes demonstrates shared pathogenesis between psoriasis and diabetes［J］. Exp Dermatol, 2017,26（11）:1112⁃1117. doi: 10.1111/exd.13393.
［91］	Hu Y, Zhu Y, Lian N, et al. Metabolic syndrome and skin diseases［J］. Front Endocrinol （Lausanne）, 2019,10:788. doi: 10.3389/fendo.2019.00788.
［92］	Schlüter K, Diehl S, Lang V, et al. Insulin resistance may contribute to upregulation of adhesion molecules on endothelial cells in psoriatic plaques［J］. Acta Derm Venereol, 2016,96（2）:162⁃168. doi: 10.2340/00015555⁃2227.
［93］	Abramczyk R, Queller JN, Rachfal AW, et al. Diabetes and psoriasis: different sides of the same prism［J］. Diabetes Metab Syndr Obes, 2020,13:3571⁃3577. doi: 10.2147/DMSO.S273147.
［94］	Pina T, Armesto S, Lopez⁃Mejias R, et al. Anti⁃TNF⁃α therapy improves insulin sensitivity in non⁃diabetic patients with psoriasis: a 6⁃month prospective study［J］. J Eur Acad Dermatol Venereol, 2015,29（7）:1325⁃1330. doi: 10.1111/jdv. 12814.
［95］	Budu⁃Aggrey A, Brumpton B, Tyrrell J, et al. Evidence of a causal relationship between body mass index and psoriasis: a mendelian randomization study［J］. PLoS Med, 2019,16（1）:e1002739. doi: 10.1371/journal.pmed.1002739.
［96］	Zhang C, Zhu KJ, Zheng HF, et al. The effect of overweight and obesity on psoriasis patients in Chinese Han population: a hospital⁃based study［J］. J Eur Acad Dermatol Venereol, 2011,25（1）:87⁃91. doi: 10.1111/j.1468⁃3083.2010.03706.x.
［97］	Enos CW, Ramos VL, McLean RR, et al. Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: a prospective analysis in Corrona Psoriasis Registry［J］. J Am Acad Dermatol, 2022,86（1）:68⁃76. doi: 10.1016/j.jaad.2021.06.883.
［98］	Shih CM, Chen CC, Chu CK, et al. The roles of lipoprotein in psoriasis［J］. Int J Mol Sci, 2020,21（3）:859. doi: 10.3390/ijms 21030859.
［99］	Snekvik I, Nilsen T, Romundstad PR, et al. Metabolic syndrome and risk of incident psoriasis: prospective data from the HUNT Study, Norway［J］. Br J Dermatol, 2019,180（1）:94⁃99. doi: 10.1111/bjd.16885.
［100］	Teijeiro A, Garrido A, Ferre A, et al. Inhibition of the IL⁃17A axis in adipocytes suppresses diet⁃induced obesity and metabolic disorders in mice［J］. Nat Metab, 2021,3（4）:496⁃512. doi: 10.1038/s42255⁃021⁃00371⁃1.
［101］	Kim BS, Lee WK, Pak K, et al. Ustekinumab treatment is associated with decreased systemic and vascular inflammation in patients with moderate⁃to⁃severe psoriasis: Feasibility study using 18F⁃fluorodeoxyglucose PET/CT［J］. J Am Acad Dermatol, 2019,80（5）:1322⁃1331. doi: 10.1016/j.jaad.2018.03.011.
［102］	Onsun N, Akaslan TÇ, Sallahoglu K, et al. Effects of TNF inhibitors and an IL12/23 inhibitor on changes in body weight and adipokine levels in psoriasis patients: a 48⁃week comparative study［J］. J Dermatolog Treat, 2022,33（3）:1727⁃1732. doi: 10.1080/09546634.2021.1901845.
［103］	Gisondi P, Conti A, Galdo G, et al. Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study［J］. Br J Dermatol, 2013,168（5）:1124⁃1127. doi: 10.1111/bjd.12235.
［104］	Bellinato F, Gisondi P, Mantovani A, et al. Risk of non⁃alcoholic fatty liver disease in patients with chronic plaque psoriasis: an updated systematic review and meta⁃analysis of observational studies［J］. J Endocrinol Invest, 2022,45（7）:1277⁃1288. doi: 10.1007/s40618⁃022⁃01755⁃0.
［105］	Ogdie A, Grewal SK, Noe MH, et al. Risk of incident liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis: a population⁃based study［J］. J Invest Dermatol, 2018,138（4）:760⁃767. doi: 10.1016/j.jid.2017.10. 024.
［106］	Torales J, Echeverría C, Barrios I, et al. Psychodermatological mechanisms of psoriasis［J］. Dermatol Ther, 2020,33（6）:e13827. doi: 10.1111/dth.13827.
［107］	Aberra TM, Joshi AA, Lerman JB, et al. Self⁃reported depression in psoriasis is associated with subclinical vascular diseases［J］. Atherosclerosis, 2016,251:219⁃225. doi: 10.1016/j.atherosclerosis.2016.05.043.
［108］	Strober B, Gooderham M, de Jong E, et al. Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry （PSOLAR）［J］. J Am Acad Dermatol, 2018,78（1）:70⁃80. doi: 10.1016/j.jaad.2017.08.051.
［109］	Kurd SK, Troxel AB, Crits⁃Christoph P, et al. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population⁃based cohort study［J］. Arch Dermatol, 2010,146（8）:891⁃895. doi: 10.1001/archdermatol.2010.186.
［110］	Chi CC, Chen TH, Wang SH, et al. Risk of suicidality in people with psoriasis: a systematic review and meta⁃analysis of cohort studies［J］. Am J Clin Dermatol, 2017,18（5）:621⁃627. doi: 10.1007/s40257⁃017⁃0281⁃1.
［111］	Chi CC, Wang J, Chen YF, et al. Risk of incident chronic kidney disease and end⁃stage renal disease in patients with psoriasis: a nationwide population⁃based cohort study［J］. J Dermatol Sci, 2015,78（3）:232⁃238. doi: 10.1016/j.jdermsci. 2015.03.012.
［112］	Svedbom A, Dalén J, Mamolo C, et al. Increased cause⁃specific mortality in patients with mild and severe psoriasis: a population⁃based Swedish register study［J］. Acta Derm Venereol, 2015,95（7）:809⁃815. doi: 10.2340/00015555⁃2095.
［113］	Ju HJ, Kim KJ, Kim DS, et al. Increased risks of autoimmune rheumatic diseases in patients with psoriasis: a nationwide population⁃based study［J］. J Am Acad Dermatol, 2018,79（4）:778⁃781. doi: 10.1016/j.jaad.2018.06.026.
［114］	Chi CC, Tung TH, Wang J, et al. Risk of uveitis among people with psoriasis: a nationwide cohort study［J］. JAMA Ophthalmol, 2017,135（5）:415⁃422. doi: 10.1001/jamaophthalmol.2017.0569.
［115］	Eppinga H, Poortinga S, Thio HB, et al. Prevalence and phenotype of concurrent psoriasis and inflammatory bowel disease［J］. Inflamm Bowel Dis, 2017,23（10）:1783⁃1789. doi: 10.1097/MIB.0000000000001169.
［116］	Liang J, Zhang S, Li Q, et al. Review of secukinumab⁃induced adverse events of special interest and its potential pathogenesis［J］. Dermatol Ther, 2022,35（8）:e15599. doi: 10.1111/dth. 15599.
［117］	Pugliese D, Daperno M, Fiorino G, et al. Real⁃life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: an IG⁃IBD study［J］. Dig Liver Dis, 2019,51（7）:972⁃977. doi: 10.1016/j.dld. 2019.03.007.
［118］	Sandborn WJ, D′Haens GR, Reinisch W, et al. Guselkumab for the treatment of Crohn′s disease: induction results from the phase 2 GALAXI⁃1 study［J］. Gastroenterology, 2022,162（6）:1650⁃1664.e8. doi: 10.1053/j.gastro.2022.01.047.
［119］	Marrie RA, Patten SB, Tremlett H, et al. Increased incidence and prevalence of psoriasis in multiple sclerosis［J］. Mult Scler Relat Disord, 2017,13:81⁃86. doi: 10.1016/j.msard.2017.02.012.
［120］	Liu CY, Tung TH, Lee CY, et al. Association of multiple sclerosis with psoriasis: a systematic review and meta⁃analysis of observational studies［J］. Am J Clin Dermatol, 2019,20（2）:201⁃208. doi: 10.1007/s40257⁃018⁃0399⁃9.
［121］	Lambert J, Segaert S, Ghislain PD, et al. Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders （BETA⁃PSO: Belgian Evidence⁃based Treatment Advice in Psoriasis; part 2）［J］. J Eur Acad Dermatol Venereol, 2020,34（9）:1914⁃1923. doi: 10.1111/jdv.16683.
［122］	Venturini M, Zanca A, Venturuzzo A, et al. Secukinumab for patients with plaque psoriasis affected by multiple sclerosis: a mini⁃review with a representative case report［J］. J Eur Acad Dermatol Venereol, 2020,34（2）:e110⁃e112. doi: 10.1111/jdv. 16035.
［123］	Dalmády S, Kemény L, Antal M, et al. Periodontitis: a newly identified comorbidity in psoriasis and psoriatic arthritis［J］. Expert Rev Clin Immunol, 2020,16（1）:101⁃108. doi: 10.1080/1744666X.2019.1700113.
［124］	Papadavid E, Dalamaga M, Vlami K, et al. Psoriasis is associated with risk of obstructive sleep apnea independently from metabolic parameters and other comorbidities: a large hospital⁃based case⁃control study［J］. Sleep Breath, 2017,21（4）:949⁃958. doi: 10.1007/s11325⁃017⁃1507⁃4.
［125］	Ungprasert P, Srivali N, Thongprayoon C. Association between psoriasis and chronic obstructive pulmonary disease: a systematic review and meta⁃analysis［J］. J Dermatolog Treat, 2016,27（4）:316⁃321. doi: 10.3109/09546634.2015.1107180.
［126］	Wi D, Wilson A, Satgé F, et al. Psoriasis and osteoporosis: a literature review［J］. Clin Exp Dermatol, 2022,47（8）:1438⁃1445. doi: 10.1111/ced.15174.
［127］	Acharya P, Mathur M. Association between psoriasis and celiac disease: a systematic review and meta⁃analysis［J］. J Am Acad Dermatol, 2020,82（6）:1376⁃1385. doi: 10.1016/j.jaad.2019.11. 039.
［128］	Molina⁃Leyva A, Jiménez⁃Moleón JJ, Naranjo⁃Sintes R, et al. Sexual dysfunction in psoriasis: a systematic review［J］. J Eur Acad Dermatol Venereol, 2015,29（4）:649⁃655. doi: 10.1111/jdv.12845.
［129］	Moro F, De Simone C, Morciano A, et al. Psoriatic patients have an increased risk of polycystic ovary syndrome: results of a cross⁃sectional analysis［J］. Fertil Steril, 2013,99（3）:936⁃942. doi: 10.1016/j.fertnstert.2012.10.040.
［130］	Eisert L, Augustin M, Bach S, et al. S2k guidelines for the treatment of psoriasis in children and adolescents ⁃ Short version part 1［J］. J Dtsch Dermatol Ges, 2019,17（8）:856⁃870. doi: 10.1111/ddg.13907.
［131］	Wu W, Debbaneh M, Moslehi H, et al. Tonsillectomy as a treatment for psoriasis: a review［J］. J Dermatolog Treat, 2014,25（6）:482⁃486. doi: 10.3109/09546634.2013.848258.
［132］	Elmets CA, Korman NJ, Prater EF, et al. Joint AAD⁃NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures［J］. J Am Acad Dermatol, 2021,84（2）:432⁃470. doi: 10.1016/j.jaad.2020.07. 087.
［133］	Arnone M, Takahashi M, Carvalho A, et al. Diagnostic and therapeutic guidelines for plaque psoriasis ⁃ Brazilian Society of Dermatology［J］. An Bras Dermatol, 2019,94（2 Suppl 1）:76⁃107. doi: 10.1590/abd1806⁃4841.2019940211.
［134］	Russo F, Vispi M, Sirna R, et al. Tuscan consensus on the use of UVBnb phototherapy in the treatment of psoriasis［J］. G Ital Dermatol Venereol, 2019,154（2）:99⁃105. doi: 10.23736/S0392⁃0488.18.06223⁃5.
［135］	中华医学会皮肤性病学分会银屑病学组. 本维莫德乳膏治疗银屑病专家指导意见［J］. 中国皮肤性病学杂志, 2021,35（6）:707⁃711. doi: 10.13735/j.cjdv.1001⁃7089.202103186.
［136］	Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology⁃National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies［J］. J Am Acad Dermatol, 2020,82（6）:1445⁃1486. doi: 10.1016/j.jaad.2020.02.044.
［137］	Torres T, Tavares Bello R, Paiva Lopes MJ, et al. Portuguese recommendations for the treatment of psoriasis with biologic therapy［J］. Eur J Dermatol, 2020,30（6）:645⁃654. doi: 10. 1684/ejd.2020.3945.
［138］	Yanovsky RL, Huang KP, Buzney EA. Optimizing narrowband UVB phototherapy regimens for psoriasis［J］. Dermatol Clin, 2020,38（1）:1⁃10. doi: 10.1016/j.det.2019.08.001.
［139］	Wang WM, Jin HZ. Biologics in the treatment of pustular psoriasis［J］. Expert Opin Drug Saf, 2020,19（8）:969⁃980. doi: 10.1080/14740338.2020.1785427.
［140］	Rossi⁃Semerano L, Piram M, Chiaverini C, et al. First clinical description of an infant with interleukin⁃36⁃receptor antagonist deficiency successfully treated with anakinra［J］. Pediatrics, 2013,132（4）:e1043⁃e1047. doi: 10.1542/peds.2012⁃3935.
［141］	Saeki H, Terui T, Morita A, et al. Japanese guidance for use of biologics for psoriasis （the 2019 version）［J］. J Dermatol, 2020,47（3）:201⁃222. doi: 10.1111/1346⁃8138.15196.
［142］	Amatore F, Villani AP, Tauber M, et al. French guidelines on the use of systemic treatments for moderate⁃to⁃severe psoriasis in adults［J］. J Eur Acad Dermatol Venereol, 2019,33（3）:464⁃483. doi: 10.1111/jdv.15340.
［143］	Podoswa⁃Ozerkovsky N, Amaya⁃Guerra M, Barba⁃Gómez JF, et al. Expert recommendations for biological treatment in patients with psoriasis［J］. Gac Med Mex, 2020,156（5）:446⁃453. doi: 10.24875/GMM.M20000441.
［144］	Chat VS, Uppal SK, Kearns DG, et al. Translating the 2020 AAD⁃NPF guidelines of care for the management of psoriasis with systemic nonbiologics to clinical practice［J］. Cutis, 2021,107（2）:99⁃103. doi: 10.12788/cutis.0177.
［145］	Lambert J, Segaert S, Ghislain PD, et al. Practical recommendations for systemic treatment in psoriasis according to age, pregnancy, metabolic syndrome, mental health, psoriasis subtype and treatment history （BETA⁃PSO: Belgian Evidence⁃based Treatment Advice in Psoriasis; part 1）［J］. J Eur Acad Dermatol Venereol, 2020,34（8）:1654⁃1665. doi: 10. 1111/jdv.16684.
［146］	Kogan N, Raimondo N, Gusis SE, et al. Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis SOLAPSO ⁃ Sociedad Latinoamericana de Psoriasis （Latin American Psoriasis Society）［J］. Int J Dermatol, 2019,58 Suppl 1:4⁃28. doi: 10.1111/ijd.14471.
［147］	Vivekanantham A, McGagh D, Coates LC. Current treatments and recommendations for Psoriatic Arthritis［J］. Best Pract Res Clin Rheumatol, 2021,35（2）:101680. doi: 10.1016/j.berh.2021. 101680.
［148］	Stiff KM, Glines KR, Porter CL, et al. Current pharmacological treatment guidelines for psoriasis and psoriatic arthritis［J］. Expert Rev Clin Pharmacol, 2018,11（12）:1209⁃1218. doi: 10. 1080/17512433.2018.1548277.
［149］	Maul JT, Anzengruber F, Conrad C, et al. Topical treatment of psoriasis vulgaris: the Swiss treatment pathway［J］. Dermatology, 2021,237（2）:166⁃178. doi: 10.1159/000512930.
［150］	Menter A, Cordoro KM, Davis D, et al. Joint American Academy of Dermatology⁃National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients［J］. J Am Acad Dermatol, 2020,82（1）:161⁃201. doi: 10. 1016/j.jaad.2019.08.049.
［151］	Kearns DG, Uppal S, Chat VS, et al. Translating the 2019 AAD⁃NPF guidelines of care for the management of psoriasis with phototherapy［J］. Cutis, 2020,106（2）:82⁃86. doi: 10.12788/cutis. 0026.
［152］	Run⁃Yan G, Sushmita P, Yu⁃Ping R. Nail psoriasis in a child observed under ultraviolet dermoscopy treated by a topical biological agent cream: a case report［J］. Int J Dermatol Venerol, 2021,4（4）:251⁃253. doi: 10.1097/JD9.000000000000 0154.
［153］	Rigopoulos D, Baran R, Chiheb S, et al. Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis: A dermatologist and nail expert group consensus［J］. J Am Acad Dermatol, 2019,81（1）:228⁃240. doi: 10.1016/j.jaad.2019.01.072.
［154］	Ghamrawi RI, Ghiam N, Wu JJ. Comparison of psoriasis guidelines for use of apremilast in the United States and Europe: a critical appraisal and comprehensive review［J］. J Dermatolog Treat, 2022,33（1）:94⁃99. doi: 10.1080/09546634. 2020.1770176.
［155］	Elmets CA, Leonardi CL, Davis D, et al. Joint AAD⁃NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities［J］. J Am Acad Dermatol, 2019,80（4）:1073⁃1113. doi: 10.1016/j.jaad.2018.11.058.
［156］	Elmets CA, Lim HW, Stoff B, et al. Joint American Academy of Dermatology⁃National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy［J］. J Am Acad Dermatol, 2019,81（3）:775⁃804. doi: 10.1016/j.jaad.2019.04.042.
［157］	Dávila⁃Seijo P, Dauden E, Descalzo MA, et al. Infections in moderate to severe psoriasis patients treated with biological drugs compared to classic systemic drugs: findings from the BIOBADADERM registry［J］. J Invest Dermatol, 2017,137（2）:313⁃321. doi: 10.1016/j.jid.2016.08.034.
［158］	Roberson ED, Bowcock AM. Psoriasis genetics: breaking the barrier［J］. Trends Genet, 2010,26（9）:415⁃423. doi: 10.1016/j.tig.2010.06.006.
［159］	Daniel BS, Orchard D. Ocular side⁃effects of topical corticosteroids: what a dermatologist needs to know［J］. Australas J Dermatol, 2015,56（3）:164⁃169. doi: 10.1111/ajd. 12292.
［160］	Harcharik S, Emer J. Steroid⁃sparing properties of emollients in dermatology［J］. Skin Therapy Lett, 2014,19（1）:5⁃10.
［161］	Jatinder Mokta, Kiran Mokta, Mahak Garg, et al. Topical calcitriol 0.5μg/Gm ointment: an effective and safe treatment of psoriasis ［J］. J Med Sci Clin Res, 2017,05（3）:19044⁃19051. doi: 10.18535/jmscr/v5i3.119. .
［162］	Highton A, Quell J. Calcipotriene ointment 0.005% for psoriasis: a safety and efficacy study. Calcipotriene Study Group［J］. J Am Acad Dermatol, 1995,32（1）:67⁃72. doi: 10.1016/0190⁃9622（95）90186⁃8.
［163］	Camarasa JM, Ortonne JP, Dubertret L. Calcitriol shows greater persistence of treatment effect than betamethasone dipropionate in topical psoriasis therapy［J］. J Dermatolog Treat, 2003,14（1）:8⁃13. doi: 10.1080/09546630305545.
［164］	Weinstein GD, Krueger GG, Lowe NJ, et al. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle⁃controlled study of safety, efficacy, and duration of therapeutic effect［J］. J Am Acad Dermatol, 1997,37（1）:85⁃92. doi: 10.1016/s0190⁃9622（97）70216⁃0.
［165］	Koo JY, Lowe NJ, Lew⁃Kaya DA, et al. Tazarotene plus UVB phototherapy in the treatment of psoriasis［J］. J Am Acad Dermatol, 2000,43（5 Pt 1）:821⁃828. doi: 10.1067/mjd.2000. 107940.
［166］	尚亚利, 聂贝贝, 王丽. 卡泊三醇倍他米松软膏治疗慢性斑块型银屑病的临床价值分析［J］. 中国合理用药探索, 2021,18（5）:77⁃80. doi: 10.3969/j.issn.2096⁃3327.2021.5.016.
［167］	Kragballe K, Austad J, Barnes L, et al. A 52⁃week randomized safety study of a calcipotriol/betamethasone dipropionate two⁃compound product （Dovobet/Daivobet/Taclonex） in the treatment of psoriasis vulgaris［J］. Br J Dermatol, 2006,154（6）:1155⁃1160. doi: 10.1111/j.1365⁃2133.2006.07236.x.
［168］	周倩倩, 陆家睛, 胡艺凡, 等. 他扎罗汀倍他米松乳膏治疗慢性斑块型银屑病的临床疗效和安全性评价［J］. 同济大学学报（医学版）, 2019,40（5）:608⁃612. doi: 10.16118/j.1008⁃0392. 2019.05.014.
［169］	Lebwohl M, Freeman AK, Chapman MS, et al. Tacrolimus ointment is effective for facial and intertriginous psoriasis［J］. J Am Acad Dermatol, 2004,51（5）:723⁃730. doi: 10.1016/j.jaad. 2004.07.011.
［170］	Gribetz C, Ling M, Lebwohl M, et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double⁃blind, randomized study［J］. J Am Acad Dermatol, 2004,51（5）:731⁃738. doi: 10.1016/j.jaad.2004.06.010.
［171］	Smith SH, Jayawickreme C, Rickard DJ, et al. Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans［J］. J Invest Dermatol, 2017,137（10）:2110⁃2119. doi: 10.1016/j.jid.2017.05.004.
［172］	Cai L, Chen GH, Lu QJ, et al. A double⁃blind, randomized, placebo⁃ and positive⁃controlled phase III trial of 1% benvitimod cream in mild⁃to⁃moderate plaque psoriasis［J］. Chin Med J （Engl）, 2020,133（24）:2905⁃2909. doi: 10.1097/CM9.0000000000001221.
［173］	中华医学会皮肤性病学分会银屑病学组. 寻常性银屑病的常用外用药物治疗［J］. 临床皮肤科杂志, 2012,41（4）:252⁃254. doi: 10.3969/j.issn.1000⁃4963.2012.04.031.
［174］	Kim JE, Kim HJ, Lew BL, et al. Consensus guidelines for the treatment of atopic dermatitis in Korea （part I）: general management and topical treatment［J］. Ann Dermatol, 2015,27（5）:563⁃577. doi: 10.5021/ad.2015.27.5.563.
［175］	中国中西医结合学会皮肤性病专业委员会环境与职业性皮肤病学组, 中华医学会皮肤性病学分会儿童学组, 中国老年保健医学研究会皮肤科分会. 特应性皮炎外用制剂合理应用及患者指导专家共识［J］. 中华皮肤科杂志, 2022,55（4）:281⁃288. doi: 10.35541/cjd.20210833.
［176］	Navrotski B, Nihi FM, Camilleri MJ, et al. Wet wrap dressings as a rescue therapy option for erythrodermic psoriasis［J］. An Bras Dermatol, 2018,93（4）:598⁃600. doi: 10.1590/abd1806⁃4841.20186414.
［177］	Mehta D, Lim HW. Ultraviolet B phototherapy for psoriasis: review of practical guidelines［J］. Am J Clin Dermatol, 2016,17（2）:125⁃133. doi: 10.1007/s40257⁃016⁃0176⁃6.
［178］	Yu Y, Yi X, Zhang Y, et al. Comparison of different incremental dose regimens of narrow⁃band ultraviolet B in skin types III to V: a prospective, randomized, single⁃blind, parallel study in patients with psoriasis［J］. J Am Acad Dermatol, 2021,84（4）:1136⁃1138. doi: 10.1016/j.jaad.2020.06.993.
［179］	Lapolla W, Yentzer BA, Bagel J, et al. A review of phototherapy protocols for psoriasis treatment［J］. J Am Acad Dermatol, 2011,64（5）:936⁃949. doi: 10.1016/j.jaad.2009.12.054.
［180］	Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy［J］. J Am Acad Dermatol, 2010,62（1）:114⁃135. doi: 10.1016/j.jaad.2009.08.026.
［181］	中华医学会皮肤性病学分会银屑病学组. 中国银屑病治疗指南（2008版）［J］. 中华皮肤科杂志, 2009,42（3）:213⁃214. doi: 10.3760/cma.j.issn.0412⁃4030.2009.03.030.
［182］	段茜, 程燕, 储蕾, 等. 中药药浴联合NB⁃UVB照射治疗寻常性银屑病疗效及安全性的系统评价［J］. 中国皮肤性病学杂志, 2013,27（2）:192⁃195.
［183］	Wolf P, Hofer A, Weger W, et al. 311 nm ultraviolet B⁃accelerated response of psoriatic lesions in adalimumab⁃treated patients［J］. Photodermatol Photoimmunol Photomed, 2011,27（4）:186⁃189. doi: 10.1111/j.1600⁃0781.2011.00594.x.
［184］	Wolf P, Hofer A, Legat FJ, et al. Treatment with 311⁃nm ultraviolet B accelerates and improves the clearance of psoriatic lesions in patients treated with etanercept［J］. Br J Dermatol, 2009,160（1）:186⁃189. doi: 10.1111/j.1365⁃2133. 2008.08926.x.
［185］	中国医师协会皮肤科医师分会规范化诊疗工作委员会, 中国医学装备协会皮肤病与皮肤美容专业委员会皮肤外科装备学组和皮肤光治疗学组. 窄谱中波紫外线家庭光疗临床应用专家共识［J］. 中华皮肤科杂志, 2019,52（3）:156⁃161. doi: 10.3760/cma.j.issn.0412⁃4030.2019.03.002.
［186］	Choi YM, Adelzadeh L, Wu JJ. Photodynamic therapy for psoriasis［J］. J Dermatolog Treat, 2015,26（3）:202⁃207. doi: 10.3109/09546634.2014.927816.
［187］	Goldust M, Raghifar R. Clinical trial study in the treatment of nail psoriasis with pulsed dye laser［J］. J Cosmet Laser Ther, 2013. doi: 10.3109/14764172.2013.854627.
［188］	Tawfik AA. Novel treatment of nail psoriasis using the intense pulsed light: a one⁃year follow⁃up study［J］. Dermatol Surg, 2014,40（7）:763⁃768. doi: 10.1111/dsu.0000000000000048.
［189］	Golusin Z, Jovanović M, Magda N, et al. Effects of Rusanda Spa balneotherapy combined with calcipotriol on plaque psoriasis［J］. Vojnosanit Pregl, 2015,72（11）:1010⁃1017. doi: 10.2298/vsp130309095g.
［190］	Klein A, Schiffner R, Schiffner⁃Rohe J, et al. A randomized clinical trial in psoriasis: synchronous balneophototherapy with bathing in Dead Sea salt solution plus narrowband UVB vs. narrowband UVB alone （TOMESA⁃study group）［J］. J Eur Acad Dermatol Venereol, 2011,25（5）:570⁃578. doi: 10.1111/j.1468⁃3083.2010.03840.x.
［191］	Yélamos O, Puig L. Systemic methotrexate for the treatment of psoriasis［J］. Expert Rev Clin Immunol, 2015,11（5）:553⁃563. doi: 10.1586/1744666X.2015.1026894.
［192］	中华医学会皮肤性病学分会银屑病专业委员会. 甲氨蝶呤治疗银屑病应用专家共识［J］. 临床皮肤科杂志, 2022,51（2）:108⁃117. doi: 10.16761/j.cnki.1000⁃4963.2022.02.015.
［193］	Ortiz Z, Shea B, Suarez⁃Almazor ME, et al. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials［J］. J Rheumatol, 1998,25（1）:36⁃43.
［194］	van Ede AE, Laan RF, Rood MJ, et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty⁃eight week, multicenter, randomized, double⁃blind, placebo⁃controlled study［J］. Arthritis Rheum, 2001,44（7）:1515⁃1524. doi: 10. 1002/1529⁃0131（200107）44:73.0.CO;2⁃7.
［195］	Maybury CM, Jabbar⁃Lopez ZK, Wong T, et al. Methotrexate and liver fibrosis in people with psoriasis: a systematic review of observational studies［J］. Br J Dermatol, 2014,171（1）:17⁃29. doi: 10.1111/bjd.12941.
［196］	Gyulai R, Bagot M, Griffiths C, et al. Current practice of methotrexate use for psoriasis: results of a worldwide survey among dermatologists［J］. J Eur Acad Dermatol Venereol, 2015,29（2）:224⁃231. doi: 10.1111/jdv.12495.
［197］	Montaudié H, Sbidian E, Paul C, et al. Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity［J］. J Eur Acad Dermatol Venereol, 2011,25 Suppl 2:12⁃18. doi: 10.1111/j. 1468⁃3083.2011.03991.x.
［198］	Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents［J］. J Am Acad Dermatol, 2009,61（3）:451⁃485. doi: 10.1016/j.jaad.2009.03. 027.
［199］	Malaviya AN. Methotrexate intolerance in the treatment of rheumatoid arthritis （RA）: effect of adding caffeine to the management regimen［J］. Clin Rheumatol, 2017,36（2）:279⁃285. doi: 10.1007/s10067⁃016⁃3398⁃3.
［200］	Gutierrez JC, Hwang K. The toxicity of methotrexate in male fertility and paternal teratogenicity［J］. Expert Opin Drug Metab Toxicol, 2017,13（1）:51⁃58. doi: 10.1080/17425255.2017.123 0198.
［201］	Amor KT, Ryan C, Menter A. The use of cyclosporine in dermatology: part I［J］. J Am Acad Dermatol, 2010,63（6）:925⁃946; quiz 947⁃948. doi: 10.1016/j.jaad.2010.02.063.
［202］	John B⁃J. The use of ciclosporin in psoriasis［J］. J Dermatolog Treat, 2005,16（5⁃6）:258⁃277
［203］	Griffiths CE, Dubertret L, Ellis CN, et al. Ciclosporin in psoriasis clinical practice: an international consensus statement［J］. Br J Dermatol, 2004,150 Suppl 67:11⁃23. doi: 10.1111/j.0366⁃077X.2004.05949.x.
［204］	Lebwohl M, Ellis C, Gottlieb A, et al. Cyclosporine consensus conference: with emphasis on the treatment of psoriasis［J］. J Am Acad Dermatol, 1998,39（3）:464⁃475. doi: 10.1016/s0190⁃9622（98）70325⁃1.
［205］	Pathirana D, Ormerod AD, Saiag P, et al. European S3⁃guidelines on the systemic treatment of psoriasis vulgaris［J］. J Eur Acad Dermatol Venereol, 2009,23 Suppl 2:1⁃70. doi: 10. 1111/j.1468⁃3083.2009.03389.x.
［206］	Camp RD, Reitamo S, Friedmann PS, et al. Cyclosporin A in severe, therapy⁃resistant atopic dermatitis: report of an international workshop, April 1993［J］. Br J Dermatol, 1993,129（2）:217⁃220. doi: 10.1111/j.1365⁃2133.1993.tb03532.x.
［207］	Griffiths CE, Katsambas A, Dijkmans BA, et al. Update on the use of ciclosporin in immune⁃mediated dermatoses［J］. Br J Dermatol, 2006,155 Suppl 2:1⁃16. doi: 10.1111/j.1365⁃2133. 2006.07343.x.
［208］	Griffiths CE, Clark CM, Chalmers RJ, et al. A systematic review of treatments for severe psoriasis［J］. Health Technol Assess, 2000,4（40）:1⁃125. doi: 10.3310/hta4400.
［209］	Faerber L, Braeutigam M, Weidinger G, et al. Cyclosporine in severe psoriasis. Results of a meta⁃analysis in 579 patients［J］. Am J Clin Dermatol, 2001,2（1）:41⁃47. doi: 10.2165/00128071⁃200102010⁃00007.
［210］	Marsili F, Travaglini M, Stinco G, et al. Effectiveness of cyclosporine A in patients with moderate to severe plaque psoriasis in a real⁃life clinical setting in Italy: the TRANSITION study［J］. J Dermatolog Treat, 2022,33（1）:401⁃407. doi: 10.1080/09546634.2020.1757017.
［211］	Michalska⁃Bańkowska A, Grabarek B, Wcisło⁃Dziadecka D, et al. The impact of diabetes and metabolic syndromes to the effectiveness of cyclosporine a pharmacotherapy in psoriatic patients［J］. Dermatol Ther, 2019,32（3）:e12881. doi: 10.1111/dth.12881.
［212］	Colombo D, Cassano N, Altomare G, et al. Psoriasis relapse evaluation with week⁃end cyclosporine A treatment: results of a randomized, double⁃blind, multicenter study［J］. Int J Immunopathol Pharmacol, 2010,23（4）:1143⁃1152. doi: 10. 1177/039463201002300418.
［213］	Singh SK, Singnarpi SR. Safety and efficacy of methotrexate （0.3 mg/kg/week） versus a combination of methotrexate （0.15 mg/kg/week） with cyclosporine （2.5 mg/kg/day） in chronic plaque psoriasis: a randomised non⁃blinded controlled trial［J］. Indian J Dermatol Venereol Leprol, 2021,87（2）:214⁃222. doi: 10.25259/IJDVL_613_19.
［214］	Ameen M, Smith HR, Barker JN. Combined mycophenolate mofetil and cyclosporin therapy for severe recalcitrant psoriasis［J］. Clin Exp Dermatol, 2001,26（6）:480⁃483. doi: 10.1046/j.1365⁃2230.2001.00870.x.
［215］	Balasubramaniam P, Stevenson O, Berth⁃Jones J. Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities［J］. Br J Dermatol, 2004,150（4）:741⁃746. doi: 10.1111/j.0007⁃0963.2004.05739.x.
［216］	Roenigk HH Jr. Acitretin combination therapy［J］. J Am Acad Dermatol, 1999,41（3 Pt 2）:S18⁃21. doi: 10.1016/s0190⁃9622（99）70361⁃0.
［217］	Clark CM, Kirby B, Morris AD, et al. Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis［J］. Br J Dermatol, 1999,141（2）:279⁃282. doi: 10. 1046/j.1365⁃2133.1999.02976.x.
［218］	Kuijpers AL, van Dooren⁃Greebe JV, van de Kerkhof PC. Failure of combination therapy with acitretin and cyclosporin A in 3 patients with erythrodermic psoriasis［J］. Dermatology, 1997,194（1）:88⁃90. doi: 10.1159/000246070.
［219］	Griffiths CE, Powles AV, McFadden J, et al. Long⁃term cyclosporin for psoriasis［J］. Br J Dermatol, 1989,120（2）:253⁃260. doi: 10.1111/j.1365⁃2133.1989.tb07790.x.
［220］	Gottlieb SL, Heftler NS, Gilleaudeau P, et al. Short⁃contact anthralin treatment augments therapeutic efficacy of cyclosporine in psoriasis: a clinical and pathologic study［J］. J Am Acad Dermatol, 1995,33（4）:637⁃645. doi: 10.1016/0190⁃9622（95）91286⁃x.
［221］	Grossman RM, Thivolet J, Claudy A, et al. A novel therapeutic approach to psoriasis with combination calcipotriol ointment and very low⁃dose cyclosporine: results of a multicenter placebo⁃controlled study［J］. J Am Acad Dermatol, 1994,31（1）:68⁃74. doi: 10.1016/s0190⁃9622（94）70138⁃5.
［222］	Sarzi⁃Puttini P, Cazzola M, Panni B, et al. Long⁃term safety and efficacy of low⁃dose cyclosporin A in severe psoriatic arthritis［J］. Rheumatol Int, 2002,21（6）:234⁃238. doi: 10.1007/s00296⁃001⁃0166⁃7.
［223］	Hong JR, Lee YW, Choe YB, et al. Risk factors for increased serum creatinine level in patients with psoriasis treated with cyclosporine in a real⁃world practice［J］. Dermatol Ther, 2019,32（3）:e12875. doi: 10.1111/dth.12875.
［224］	Somech R, Doyle J. Pseudotumor cerebri after allogeneic bone marrow transplant associated with cyclosporine a use for graft⁃versus⁃host disease prophylaxis［J］. J Pediatr Hematol Oncol, 2007,29（1）:66⁃68. doi: 10.1097/MPH.0b013e318030ac3b.
［225］	Higgins E, Munro C, Marks J, et al. Relapse rates in moderately severe chronic psoriasis treated with cyclosporin A［J］. Br J Dermatol, 1989,121（1）:71⁃74. doi: 10.1111/j.1365⁃2133.1989.tb01402.x.
［226］	Ho VC, Griffiths CE, Berth⁃Jones J, et al. Intermittent short courses of cyclosporine microemulsion for the long⁃term management of psoriasis: a 2⁃year cohort study［J］. J Am Acad Dermatol, 2001,44（4）:643⁃651. doi: 10.1067/mjd.2001.112400.
［227］	Rosmarin DM, Lebwohl M, Elewski BE, et al. Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference［J］. J Am Acad Dermatol, 2010,62（5）:838⁃853. doi: 10.1016/j.jaad.2009.05.017.
［228］	Zouboulis CC. Retinoids⁃⁃which dermatological indications will benefit in the near future?［J］. Skin Pharmacol Appl Skin Physiol, 2001,14（5）:303⁃315. doi: 10.1159/000056361.
［229］	Sarkar R, Chugh S, Garg VK. Acitretin in dermatology［J］. Indian J Dermatol Venereol Leprol, 2013,79（6）:759⁃771. doi: 10.4103/0378⁃6323.120721.
［230］	杨林芳, 曹玉萍, 张孟丽, 等. 维A酸的抗炎作用及在炎症性皮肤病中的应用［J］. 国际皮肤性病学杂志, 2016,42（5）:405⁃408. doi: 10.3760/cma.j.issn.1673⁃4173.2016.05.013.
［231］	Warren RB, Griffiths CE. Systemic therapies for psoriasis: methotrexate, retinoids, and cyclosporine［J］. Clin Dermatol, 2008,26（5）:438⁃447. doi: 10.1016/j.clindermatol.2007.11.006.
［232］	Iwata M, Eshima Y, Kagechika H. Retinoic acids exert direct effects on T cells to suppress Th1 development and enhance Th2 development via retinoic acid receptors［J］. Int Immunol, 2003,15（8）:1017⁃1025. doi: 10.1093/intimm/dxg101.
［233］	Niu X, Cao W, Ma H, et al. Acitretin exerted a greater influence on T⁃helper （Th）1 and Th17 than on Th2 cells in treatment of psoriasis vulgaris［J］. J Dermatol, 2012,39（11）:916⁃921. doi: 10.1111/j.1346⁃8138.2012.01637.x.
［234］	McNamara PJ, Jewell RC, Jensen BK, et al. Food increases the bioavailability of acitretin［J］. J Clin Pharmacol, 1988,28（11）:1051⁃1055. doi: 10.1002/j.1552⁃4604.1988.tb03129.x.
［235］	Brindley CJ. Overview of recent clinical pharmacokinetic studies with acitretin （Ro 10⁃1670, etretin）［J］. Dermatologica, 1989,178（2）:79⁃87. doi: 10.1159/000248397.
［236］	Berbis P. Retinoids: mechanisms of action［J］. Ann Dermatol Venereol, 2010,137 Suppl 3:S97⁃S103. doi: 10.1016/S0151⁃9638（10）70036⁃3.
［237］	孙建方, 温海, 郝飞, 等. 阿维A治疗寻常性银屑病120例［J］. 中华皮肤科杂志, 2008,41（3）:204⁃205. doi: 10.3321/j.issn:0412⁃4030.2008.03.036.
［238］	Ozawa A, Ohkido M, Haruki Y, et al. Treatments of generalized pustular psoriasis: a multicenter study in Japan［J］. J Dermatol, 1999,26（3）:141⁃149. doi: 10.1111/j.1346⁃8138.1999.tb03444.x.
［239］	Paul C, Gallini A, Maza A, et al. Evidence⁃based recommendations on conventional systemic treatments in psoriasis: systematic review and expert opinion of a panel of dermatologists［J］. J Eur Acad Dermatol Venereol, 2011,25 Suppl 2:2⁃11. doi: 10.1111/j.1468⁃3083.2011.03990.x.
［240］	Ergun T, Seckin Gencosmanoglu D, Alpsoy E, et al. Efficacy, safety and drug survival of conventional agents in pediatric psoriasis: a multicenter, cohort study［J］. J Dermatol, 2017,44（6）:630⁃634. doi: 10.1111/1346⁃8138.13713.
［241］	Daudén E, Puig L, Ferrándiz C, et al. Consensus document on the evaluation and treatment of moderate⁃to⁃severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology［J］. J Eur Acad Dermatol Venereol, 2016,30 Suppl 2:1⁃18. doi: 10.1111/jdv.13542.
［242］	Hoffman MB, Farhangian M, Feldman SR. Psoriasis during pregnancy: characteristics and important management recommendations［J］. Expert Rev Clin Immunol, 2015,11（6）:709⁃720. doi: 10.1586/1744666X.2015.1037742.
［243］	Gollnick HP. Oral retinoids⁃⁃efficacy and toxicity in psoriasis［J］. Br J Dermatol, 1996,135 Suppl 49:6⁃17. doi: 10.1111/j. 1365⁃2133.1996.tb15661.x.
［244］	Ling MR. Acitretin: optimal dosing strategies［J］. J Am Acad Dermatol, 1999,41（3 Pt 2）:S13⁃S17. doi: 10.1016/s0190⁃9622（99）70360⁃9.
［245］	Menter MA, See JA, Amend WJ, et al. Proceedings of the Psoriasis Combination and Rotation Therapy Conference. Deer Valley, Utah, Oct. 7⁃9, 1994［J］. J Am Acad Dermatol, 1996,34（2 Pt 1）:315⁃321. doi: 10.1016/s0190⁃9622（96）80148⁃4.
［246］	Geiger JM, Walker M. Is there a reproductive safety risk in male patients treated with acitretin （neotigason/soriatane?［J］. Dermatology, 2002,205（2）:105⁃107. doi: 10.1159/000063893.
［247］	Kumar P, Das A, Lal NR, et al. Safety of important dermatological drugs （retinoids, immune suppressants, anti androgens and thalidomide） in reproductively active males with respect to pregnancy outcome: a brief review of literature［J］. Indian J Dermatol Venereol Leprol, 2018,84（5）:539⁃546. doi: 10.4103/ijdvl.IJDVL_77_17.
［248］	冯素英, 林麟, 靳培英. 维A酸类药的临床应用、不良反应及对策［J］. 中华皮肤科杂志, 2003,36（9）:543⁃545. doi: 10. 3760/j.issn:0412⁃4030.2003.09.038.
［249］	Gu W, Zhao G, Shi F. Acitretin⁃induced retinoic acid syndrome［J］. J Am Acad Dermatol, 2011,65（5）:e148⁃e149. doi: 10.1016/ j.jaad.2011.05.009.
［250］	Lo Y, Tsai TF. Updates on the treatment of erythrodermic psoriasis［J］. Psoriasis （Auckl）, 2021,11:59⁃73. doi: 10.2147/PTT.S288345.
［251］	谢阳, 万苗坚. 皮肤科常用糖皮质激素类药物的类型及适应症［J］. 中国医学文摘（皮肤科学）, 2015,32（3）:283⁃288.
［252］	张建中. 糖皮质激素的分类及其在皮肤科的应用［J］. 中国医学文摘（皮肤科学）, 2015,32（3）:241⁃247.
［253］	Munro DD. Azathioprine in psoriasis［J］. Proc R Soc Med, 1973,66（8）:747⁃748.
［254］	Dalaker M, Bonesrønning JH. Long⁃term maintenance treatment of moderate⁃to⁃severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort［J］. J Eur Acad Dermatol Venereol, 2009,23（3）:277⁃282. doi: 10.1111/j.1468⁃3083.2008.03039.x.
［255］	Wilson AG, Clark I, Heard SR, et al. Immunoblotting of streptococcal antigens in guttate psoriasis［J］. Br J Dermatol, 1993,128（2）:151⁃158. doi: 10.1111/j.1365⁃2133.1993.tb15144. x.
［256］	Koufakis T, Gabranis I. First presentation of guttate psoriasis triggered by acute tonsillitis［J］. Pan Afr Med J, 2014,17:273. doi: 10.11604/pamj.2014.17.273.421.
［257］	Macmillan AL, Champion RH. Generalized pustular psoriasis treated with dapsone［J］. Br J Dermatol, 1973,88（2）:183⁃185. doi: 10.1111/j.1365⁃2133.1973.tb07523.x.
［258］	Guglielmetti A, Conlledo R, Bedoya J, et al. Inverse psoriasis involving genital skin folds: successful therapy with dapsone［J］. Dermatol Ther （Heidelb）, 2012,2（1）:15. doi: 10.1007/s13555⁃012⁃0015⁃5.
［259］	黄琼, 杨勤萍, 方栩, 等. 重组人Ⅱ型肿瘤坏死因子受体⁃抗体融合蛋白治疗寻常性银屑病多中心、随机、双盲试验［J］. 中华皮肤科杂志, 2007,40（11）:655⁃658. doi: 10.3760/j.issn:0412⁃4030.2007.11.001.
［260］	Yang HZ, Wang K, Jin HZ, et al. Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double⁃blind, placebo⁃controlled multicenter trial［J］. Chin Med J （Engl）, 2012,125（11）:1845⁃1851.
［261］	Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque⁃type psoriasis: a randomized, double⁃blind, placebo⁃controlled trial［J］. J Am Acad Dermatol, 2004,51（4）:534⁃542. doi: 10.1016/j.jaad.2004.02.021.
［262］	Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate⁃to⁃severe psoriasis: a phase III, multicentre, double⁃blind trial［J］. Lancet, 2005,366（9494）: 1367⁃1374. doi: 10.1016/S0140⁃6736（05）67566⁃6.
［263］	Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial［J］. Ann Rheum Dis, 2005,64（8）:1150⁃1157. doi: 10.1136/ard.2004.032268.
［264］	Cai L, Gu J, Zheng J, et al. Efficacy and safety of adalimumab in Chinese patients with moderate⁃to⁃severe plaque psoriasis: results from a phase 3, randomized, placebo⁃controlled, double⁃blind study［J］. J Eur Acad Dermatol Venereol, 2017,31（1）:89⁃95. doi: 10.1111/jdv.13746.
［265］	Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial［J］. J Am Acad Dermatol, 2008,58（1）:106⁃115. doi: 10.1016/j.jaad.2007.09.010.
［266］	Papp K, Thaçi D, Marcoux D, et al. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double⁃blind, phase 3 trial［J］. Lancet, 2017,390（10089）:40⁃49. doi: 10.1016/S0140⁃6736（17）31189⁃3.
［267］	刘鸿伟, 胡雪英, 雷东春, 等. 阿达木单抗治疗重度斑块状银屑病的临床观察［J］. 中华皮肤科杂志, 2020,53（9）:744⁃746. doi: 10.35541/cjd.20190757.
［268］	Lanna C, Zangrilli A, Bavetta M, et al. Efficacy and safety of adalimumab in difficult⁃to⁃treat psoriasis［J］. Dermatol Ther, 2020,33（3）:e13374. doi: 10.1111/dth.13374.
［269］	Lee A, Scott LJ. Certolizumab pegol: a review in moderate to severe plaque psoriasis［J］. BioDrugs, 2020,34（2）:235⁃244. doi: 10.1007/s40259⁃020⁃00416⁃z.
［270］	Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin⁃12/23 monoclonal antibody, in patients with psoriasis: 52⁃week results from a randomised, double⁃blind, placebo⁃controlled trial （PHOENIX 2）［J］. Lancet, 2008,371（9625）:1675⁃1684. doi: 10.1016/S0140⁃6736（08）60726⁃6.
［271］	Zhu X, Zheng M, Song M, et al. Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque⁃type psoriasis: results from a phase 3 clinical trial （LOTUS）［J］. J Drugs Dermatol, 2013,12（2）:166⁃174.
［272］	Kimball AB, Papp KA, Wasfi Y, et al. Long⁃term efficacy of ustekinumab in patients with moderate⁃to⁃severe psoriasis treated for up to 5 years in the PHOENIX 1 study［J］. J Eur Acad Dermatol Venereol, 2013,27（12）:1535⁃1545. doi: 10.1111/ jdv.12046.
［273］	Landells I, Marano C, Hsu MC, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate⁃to⁃severe plaque psoriasis: results of the randomized phase 3 CADMUS study［J］. J Am Acad Dermatol, 2015,73（4）:594⁃603. doi: 10. 1016/j.jaad.2015.07.002.
［274］	Philipp S, Menter A, Nikkels AF, et al. Ustekinumab for the treatment of moderate⁃to⁃severe plaque psoriasis in paediatric patients （≥ 6 to < 12 years of age）: efficacy, safety, pharmacokinetic and biomarker results from the open⁃label CADMUS Jr study［J］. Br J Dermatol, 2020,183（4）:664⁃672. doi: 10.1111/bjd.19018.
［275］	Cai L, Zhang JZ, Yao X, et al. Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis［J］. Chin Med J （Engl）, 2020,133（22）:2665⁃2673. doi: 10.1097/CM9.00000 00000001163.
［276］	Huang H, Cai ML, Hong XJ, et al. Real⁃world data on the use of secukinumab as treatment for moderate⁃to⁃severe psoriasis in Chinese patients［J］. Eur J Dermatol, 2020,30（5）:554⁃560. doi: 10.1684/ejd.2020.3878.
［277］	McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti⁃interleukin⁃17A monoclonal antibody, in patients with psoriatic arthritis （FUTURE 2）: a randomised, double⁃blind, placebo⁃controlled, phase 3 trial［J］. Lancet, 2015,386（9999）:1137⁃1146. doi: 10.1016/S0140⁃6736（15）61134⁃5.
［278］	Xia L, Jie Z, Wei⁃Li P, et al. Efficacy and safety of ixekizumab in Chinese patients with moderate⁃to⁃severe plaque psoriasis: 60⁃week results from a phase 3 study［J］. Int J Dermatol Venerol, 2022,5（4）:181⁃190. doi: 10.1097/JD9.000000000000 0244.
［279］	Blauvelt A, Lebwohl MG, Mabuchi T, et al. Long⁃term efficacy and safety of ixekizumab: a 5⁃year analysis of the UNCOVER⁃3 randomized controlled trial［J］. J Am Acad Dermatol, 2021,85（2）:360⁃368. doi: 10.1016/j.jaad.2020.11.022.
［280］	Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin⁃17A specific monoclonal antibody, for the treatment of biologic⁃naive patients with active psoriatic arthritis: results from the 24⁃week randomised, double⁃blind, placebo⁃controlled and active （adalimumab）⁃controlled period of the phase III trial SPIRIT⁃P1［J］. Ann Rheum Dis, 2017,76（1）:79⁃87. doi: 10.1136/annrheumdis⁃2016⁃209709.
［281］	Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis［J］. N Engl J Med, 2015,373（14）:1318⁃1328. doi: 10.1056/NEJMoa 1503824.
［282］	Puig L, Lebwohl M, Bachelez H, et al. Long⁃term efficacy and safety of brodalumab in the treatment of psoriasis: 120⁃week results from the randomized, double⁃blind, placebo⁃ and active comparator⁃controlled phase 3 AMAGINE⁃2 trial［J］. J Am Acad Dermatol, 2020,82（2）:352⁃359. doi: 10.1016/j.jaad.2019. 05.095.
［283］	Freitas E, Blauvelt A, Torres T. Bimekizumab for the treatment of psoriasis［J］. Drugs, 2021,81（15）:1751⁃1762. doi: 10.1007/s40265⁃021⁃01612⁃z.
［284］	Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate⁃to⁃severe psoriasis （ECLIPSE）: results from a phase 3, randomised controlled trial［J］. Lancet, 2019,394（10201）:831⁃839. doi: 10.1016/S0140⁃6736（19）31773⁃8.
［285］	Reich K, Griffiths C, Gordon KB, et al. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials［J］. J Am Acad Dermatol, 2020,82（4）:936⁃945. doi: 10.1016/j.jaad.2019.11.040.
［286］	Reich K, Gordon KB, Strober BE, et al. Five⁃year maintenance of clinical response and health⁃related quality of life improvements in patients with moderate⁃to⁃severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2［J］. Br J Dermatol, 2021,185（6）:1146⁃1159. doi: 10.1111/bjd.20568.
［287］	Zhuang JY, Li JS, Zhong YQ, et al. Evaluation of short⁃term （16⁃week） effectiveness and safety of guselkumab in patients with psoriasis: a prospective real⁃life study on the Chinese population［J］. Dermatol Ther, 2021,34（5）:e15054. doi: 10. 1111/dth.15054.
［288］	Liu H, Huang H, Zhang X. Long⁃term effectiveness and safety of guselkumab in Chinese patients with moderate⁃to⁃severe plaque psoriasis in clinical practice［Z/OL］. ［2022⁃09⁃12］. https://eadvcongress2022.org/scientific/abstracts/.
［289］	Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic⁃naive patients with active psoriatic arthritis （DISCOVER⁃2）: a double⁃blind, randomised, placebo⁃controlled phase 3 trial［J］. Lancet, 2020,395（10230）:1126⁃1136. doi: 10.1016/S0140⁃6736（20）30263⁃4.
［290］	Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis （reSURFACE 1 and reSURFACE 2）: results from two randomised controlled, phase 3 trials［J］. Lancet, 2017,390（10091）:276⁃288. doi: 10.1016/S0140⁃6736（17）31279⁃5.
［291］	Papp KA, Blauvelt A, Bukhalo M, et al. Risankizumab versus ustekinumab for moderate⁃to⁃severe plaque psoriasis［J］. N Engl J Med, 2017,376（16）:1551⁃1560. doi: 10.1056/NEJMoa 1607017.
［292］	Takeichi T, Akiyama M. Generalized pustular psoriasis: clinical management and update on autoinflammatory aspects［J］. Am J Clin Dermatol, 2020,21（2）:227⁃236. doi: 10.1007/s40257⁃019⁃00492⁃0.
［293］	Bachelez H, Choon SE, Marrakchi S, et al. Trial of spesolimab for generalized pustular psoriasis［J］. N Engl J Med, 2021,385（26）:2431⁃2440. doi: 10.1056/NEJMoa2111563.
［294］	Owczarek W, Walecka I, Lesiak A, et al. The use of biological drugs in psoriasis patients prior to pregnancy, during pregnancy and lactation: a review of current clinical guidelines［J］. Postepy Dermatol Alergol, 2020,37（6）:821⁃830. doi: 10.5114/ada.2020.102089.
［295］	Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions［J］. Gastroenterology, 2017,152（6）:1297⁃1309. doi: 10.1053/j.gastro. 2017.02.009.
［296］	肿瘤坏死因子拮抗剂应用中结核病预防与管理专家建议组. 肿瘤坏死因子拮抗剂应用中结核病预防与管理专家共识［J］. 中华风湿病学杂志, 2013,17（8）:508⁃512. doi: 10.3760/ cma.j.issn.1007⁃7480.2013.08.002.
［297］	Kamiya K, Komine M, Ohtsuki M. Biologics for psoriasis during the COVID⁃19 pandemic［J］. J Clin Med, 2021,10（7）:1390. doi: 10.3390/jcm10071390.
［298］	Poelman SM, Keeling CP, Metelitsa AI. Practical guidelines for managing patients with psoriasis on biologics: an update［J］. J Cutan Med Surg, 2019,23（1_suppl）:3S⁃12S. doi: 10.1177/1203475418811347.
［299］	Torres AE, Lyons AB, Hamzavi IH, et al. Role of phototherapy in the era of biologics［J］. J Am Acad Dermatol, 2021,84（2）:479⁃485. doi: 10.1016/j.jaad.2020.04.095.
［300］	Armstrong AW, Bagel J, Van Voorhees AS, et al. Combining biologic therapies with other systemic treatments in psoriasis: evidence⁃based, best⁃practice recommendations from the Medical Board of the National Psoriasis Foundation［J］. JAMA Dermatol, 2015,151（4）:432⁃438. doi: 10.1001/jamadermatol. 2014.3456.
［301］	Liu LF, Chen JS, Gu J, et al. Etanercept biosimilar （recombinant human tumor necrosis factor⁃α receptor II: IgG Fc fusion protein） and methotrexate combination therapy in Chinese patients with moderate⁃to⁃severe plaque psoriasis: a multicentre, randomized, double⁃blind, placebo⁃controlled trial［J］. Arch Dermatol Res, 2020,312（6）:437⁃445. doi: 10.1007/s00403⁃019⁃02024⁃6.
［302］	Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 （PDE4） inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial （Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis ［ESTEEM］ 1）［J］. J Am Acad Dermatol, 2015,73（1）:37⁃49. doi: 10.1016/j.jaad.2015.03.049.
［303］	Reich K, Gooderham M, Green L, et al. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate⁃to⁃severe plaque psoriasis: 52⁃week results from a phase IIIb, randomized, placebo⁃controlled trial （LIBERATE）［J］. J Eur Acad Dermatol Venereol, 2017,31（3）:507⁃517. doi: 10.1111/jdv.14015.
［304］	Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate⁃to⁃severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial （ESTEEM 2）［J］. Br J Dermatol, 2015,173（6）:1387⁃1399. doi: 10.1111/bjd.14164.
［305］	Papp KA, Menter MA, Abe M, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo⁃controlled, phase III trials［J］. Br J Dermatol, 2015,173（4）:949⁃961. doi: 10.1111/bjd. 14018.
［306］	McInnes IB, Anderson JK, Magrey M, et al. Trial of upadacitinib and adalimumab for psoriatic arthritis［J］. N Engl J Med, 2021,384（13）:1227⁃1239. doi: 10.1056/NEJMoa2022 516.
［307］	Mease PJ, Lertratanakul A, Anderson JK, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT⁃PsA 2［J］. Ann Rheum Dis, 2021,80（3）:312⁃320. doi: 10.1136/annrheumdis⁃2020⁃218870.
［308］	Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52⁃week, randomized, double⁃blinded, placebo⁃controlled phase 3 POETYK PSO⁃1 trial［J］. J Am Acad Dermatol, 2023,88（1）:29⁃39. doi: 10.1016/j.jaad.2022.07.002.
［309］	Gilbert SF. Developmental biology［M］. 6th ed. Sunerland（MA）: Sinauer Associates, 2000.
［310］	Farber EM, Rein G, Lanigan SW. Stress and psoriasis. Psychoneuroimmunologic mechanisms［J］. Int J Dermatol, 1991,30（1）:8⁃12. doi: 10.1111/j.1365⁃4362.1991.tb05870.x.
［311］	Marek⁃Jozefowicz L, Czajkowski R, Borkowska A, et al. The brain⁃skin axis in psoriasis⁃psychological, psychiatric, hormonal, and dermatological aspects［J］. Int J Mol Sci, 2022,23（2）:669. doi: 10.3390/ijms23020669.
［312］	杨雪琴, 李铀, 李炜. 银屑病患者的心率变异性研究［J］. 空军总医院学报, 1996,（4）:193.
［313］	杨雪琴, 邵黎, 那爱华. 银屑病患者血清中神经免疫蛋白与淋巴细胞转化的研究［J］. 中华皮肤科杂志, 1998,31（2）:97. doi: 10.3760/j.issn:0412⁃4030.1998.02.011.
［314］	张力军, 杨雪琴, 孟如松, 等. 银屑病皮损及非皮损中垂体腺苷酸环化酶激活肽及其受体的研究［J］. 中华皮肤科杂志, 2005,38（3）:146⁃147. doi: 10.3760/j.issn:0412⁃4030.2005.03. 004.
［315］	Koo J, Lebwohl A. Psycho dermatology: the mind and skin connection［J］. Am Fam Physician, 2001,64（11）:1873⁃1878.
［316］	Jafferany M, Ferreira BR, Abdelmaksoud A, et al. Management of psychocutaneous disorders: a practical approach for dermatologists［J］. Dermatol Ther, 2020,33（6）:e13969. doi: 10.1111/dth.13969.
［317］	Dalgard FJ, Gieler U, Tomas⁃Aragones L, et al. The psychological burden of skin diseases: a cross⁃sectional multicenter study among dermatological out⁃patients in 13 European countries［J］. J Invest Dermatol, 2015,135（4）:984⁃991. doi: 10.1038/jid.2014.530.
［318］	Fortune DG, Richards HL, Kirby B, et al. Successful treatment of psoriasis improves psoriasis⁃specific but not more general aspects of patients′ well⁃being［J］. Br J Dermatol, 2004,151（6）:1219⁃1226. doi: 10.1111/j.1365⁃2133.2004.06222.x.
［319］	Sampogna F, Tabolli S, Abeni D, et al. The impact of changes in clinical severity on psychiatric morbidity in patients with psoriasis: a follow⁃up study［J］. Br J Dermatol, 2007,157（3）:508⁃513. doi: 10.1111/j.1365⁃2133.2007.08071.x.
［320］	McAleer MA, Mason DL, Cunningham S, et al. Alcohol misuse in patients with psoriasis: identification and relationship to disease severity and psychological distress［J］. Br J Dermatol, 2011,164（6）:1256⁃1261. doi: 10.1111/j.1365⁃2133.2011.10345. x.
［321］	Moon HS, Mizara A, McBride SR. Psoriasis and psycho⁃dermatology［J］. Dermatol Ther （Heidelb）, 2013,3（2）:117⁃130. doi: 10.1007/s13555⁃013⁃0031⁃0.
［322］	Ryan C, Sadlier M, De Vol E, et al. Genital psoriasis is associated with significant impairment in quality of life and sexual functioning［J］. J Am Acad Dermatol, 2015,72（6）:978⁃983. doi: 10.1016/j.jaad.2015.02.1127.
［323］	Sampogna F, Puig L, Spuls P, et al. Prevalence of alexithymia in patients with psoriasis and its association with disease burden: a multicentre observational study［J］. Br J Dermatol, 2017,176（5）:1195⁃1203. doi: 10.1111/bjd.15243.
［324］	Singh S, Taylor C, Kornmehl H, et al. Psoriasis and suicidality: a systematic review and meta⁃analysis［J］. J Am Acad Dermatol, 2017,77（3）:425⁃440.e2. doi: 10.1016/j.jaad.2017.05.019.
［325］	王爱燕, 崔艳霞, 张华梅, 等. 银屑病患者心理行为干预的研究进展［J］. 中国医药指南, 2017,15（1）:16⁃16,17.
［326］	Mercy K, Kwasny M, Cordoro KM, et al. Clinical manifestations of pediatric psoriasis: results of a multicenter study in the United States［J］. Pediatr Dermatol, 2013,30（4）:424⁃428. doi: 10.1111/pde.12072.
［327］	Raychaudhuri SP, Gross J. A comparative study of pediatric onset psoriasis with adult onset psoriasis［J］. Pediatr Dermatol, 2000,17（3）:174⁃178. doi: 10.1046/j.1525⁃1470.2000.01746.x.
［328］	Beani JC, Jeanmougin M. Narrow⁃band UVB therapy in psoriasis vulgaris: good practice guideline and recommendations of the French Society of Photodermatology［J］. Ann Dermatol Venereol, 2010,137（1）:21⁃31. doi: 10.1016/j.annder.2009.12. 004.
［329］	Pavlovsky M, Baum S, Shpiro D, et al. Narrow band UVB: is it effective and safe for paediatric psoriasis and atopic dermatitis?［J］. J Eur Acad Dermatol Venereol, 2011,25（6）:727⁃729. doi: 10.1111/j.1468⁃3083.2010.03832.x.
［330］	Pugashetti R, Koo J. Phototherapy in pediatric patients: choosing the appropriate treatment option［J］. Semin Cutan Med Surg, 2010,29（2）:115⁃120. doi: 10.1016/j.sder.2010.03.006.
［331］	Lee CS, Li K. A review of acitretin for the treatment of psoriasis［J］. Expert Opin Drug Saf, 2009,8（6）:769⁃779. doi: 10.1517/14740330903393732.
［332］	Lansang P, Bergman JN, Fiorillo L, et al. Management of pediatric plaque psoriasis using biologics［J］. J Am Acad Dermatol, 2020,82（1）:213⁃221. doi: 10.1016/j.jaad.2019.05. 056.
［333］	Windschall D, Müller T, Becker I, et al. Safety and efficacy of etanercept in children with the JIA categories extended oligoarthritis, enthesitis⁃related arthritis and psoriasis arthritis［J］. Clin Rheumatol, 2015,34（1）:61⁃69. doi: 10.1007/s10067⁃014⁃2744⁃6.
［334］	Raychaudhuri SP, Navare T, Gross J, et al. Clinical course of psoriasis during pregnancy［J］. Int J Dermatol, 2003,42（7）:518⁃520. doi: 10.1046/j.1365⁃4362.2003.01760.x.
［335］	Chi CC, Mayon⁃White RT, Wojnarowska FT. Safety of topical corticosteroids in pregnancy: a population⁃based cohort study［J］. J Invest Dermatol, 2011,131（4）:884⁃891. doi: 10.1038/jid.2010.392.
［336］	Andersson NW, Skov L, Andersen JT. Evaluation of topical corticosteroid use in pregnancy and risk of newborns being small for gestational age and having low birth weight［J］. JAMA Dermatol, 2021,157（7）:788⁃795. doi: 10.1001/jamadermatol. 2021.1090.
［337］	Uchiyama H, Suzuki T, Koike Y, et al. Reproductive and developmental toxicity studies of calcipotriol （MC903）: （3）⁃⁃a teratogenicity study in rabbits by subcutaneous administration［J］. J Toxicol Sci, 1996,21 Suppl 2:425⁃438. doi: 10.2131/jts.21.supplementii_425.
［338］	El⁃Saie LT, Rabie AR, Kamel MI, et al. Effect of narrowband ultraviolet B phototherapy on serum folic acid levels in patients with psoriasis［J］. Lasers Med Sci, 2011,26（4）:481⁃485. doi: 10.1007/s10103⁃011⁃0895⁃0.
［339］	Förger F, Zbinden A, Villiger PM. Certolizumab treatment during late pregnancy in patients with rheumatic diseases: Low drug levels in cord blood but possible risk for maternal infections. A case series of 13 patients［J］. Joint Bone Spine, 2016,83（3）:341⁃343. doi: 10.1016/j.jbspin.2015.07.004.
［340］	Förger F, Villiger PM. Treatment of rheumatoid arthritis during pregnancy: present and future［J］. Expert Rev Clin Immunol, 2016,12（9）:937⁃944. doi: 10.1080/1744666X.2016.1184973.
［341］	Kurizky PS, Ferreira Cde C, Nogueira LS, et al. Treatment of psoriasis and psoriatic arthritis during pregnancy and breastfeeding［J］. An Bras Dermatol, 2015,90（3）:367⁃375. doi: 10.1590/abd1806⁃4841.20153113.
［342］	Pham⁃Huy A, Top KA, Constantinescu C, et al. The use and impact of monoclonal antibody biologics during pregnancy［J］. CMAJ, 2021,193（29）:E1129⁃E1136. doi: 10.1503/cmaj.202391.
［343］	Clowse ME. The use of anti⁃TNFα medications for rheumatologic disease in pregnancy［J］. Int J Womens Health, 2010,2:199⁃209. doi: 10.2147/ijwh.s6029.
［344］	Porter ML, Lockwood SJ, Kimball AB. Update on biologic safety for patients with psoriasis during pregnancy［J］. Int J Womens Dermatol, 2017,3（1）:21⁃25. doi: 10.1016/j.ijwd.2016. 12.003.
［345］	Balato N, Patruno C, Napolitano M, et al. Managing moderate⁃to⁃severe psoriasis in the elderly［J］. Drugs Aging, 2014,31（4）:233⁃238. doi: 10.1007/s40266⁃014⁃0156⁃6.
［346］	Parslew R, Traulsen J. Efficacy and local safety of a calcipotriol/ betamethasone dipropionate ointment in elderly patients with psoriasis vulgaris［J］. Eur J Dermatol, 2005,15（1）:37⁃39.
［347］	Bulur I, Erdogan HK, Aksu AE, et al. The efficacy and safety of phototherapy in geriatric patients: a retrospective study［J］. An Bras Dermatol, 2018,93（1）:33⁃38. doi: 10.1590/abd1806⁃4841. 20185468.
［348］	Garber C, Plotnikova N, Au SC, et al. Biologic and conventional systemic therapies show similar safety and efficacy in elderly and adult patients with moderate to severe psoriasis［J］. J Drugs Dermatol, 2015,14（8）:846⁃852.
［349］	Di Caprio R, Caiazzo G, Cacciapuoti S, et al. Safety concerns with current treatments for psoriasis in the elderly［J］. Expert Opin Drug Saf, 2020,19（4）:523⁃531. doi: 10.1080/14740338. 2020.1728253.
［350］	李茂, 郝平生. 从伏邪学说论治寻常型银屑病［J］. 四川中医, 2020,38（1）:28⁃30.
［351］	Zhou D, Chen W, Li X, et al. Evidence⁃based practice guideline of Chinese herbal medicine for psoriasis vulgaris （Bai Bi）［J］. Eur J Integr Med, 2014,6（2）:135⁃146.
［352］	张思文, 陈湘君, 刘靖. 基于伏气学说的犀角地黄汤用于寻常型银屑病血热证［J］. 中国中医药信息杂志, 2020,27（3）:126⁃127. doi: 10.3969/j.issn.1005⁃5304.201810122.
［353］	Sun L, Li T, Zhou D, et al. Efficacy and safety of Liangxue Jiedu decoction for the treatment of progressive psoriasis vulgaris: a multicenter, randomized, controlled study［J］. J Tradit Chin Med, 2020,40（2）:296⁃304.
［354］	周冬梅, 王萍. 凉血活血汤治疗进行期银屑病140例临床观察［J］. 北京中医, 2000,19（3）:23⁃24. doi: 10.3969/j.issn.1674⁃1307.2000.03.012.
［355］	李福伦, 李斌, 徐蓉, 等. 芩珠凉血合剂治疗血热证银屑病的随机对照临床研究［J］. 中西医结合学报, 2008,6（6）:586⁃590.
［356］	崔彦君. 活血散瘀汤联合阿维A胶囊对寻常型银屑病（血瘀证）的临床疗效［J］. 中外医学研究, 2020,18（35）:144⁃146. doi: 10.14033/j.cnki.cfmr.2020.35.055.
［357］	Li T, Zhou D, Xu X, et al. Effect of Traditional Chinese Medicine plus narrow⁃band medium⁃wave ultraviolet B radiation on moderate⁃to⁃severe psoriasis vulgaris in a case series［J］. J Tradit Chin Med, 2019,39（5）:692⁃699.
［358］	Yao DN, Lu CJ, Wen ZH, et al. Comparison of PSORI⁃CM01 granules and Yinxieling tablets for patients with chronic plaque psoriasis: a pilot study for a randomized, double⁃blinded, double⁃dummy, multicentre trial［J］. Ann Palliat Med, 2021,10（2）:2036⁃2047. doi: 10.21037/apm⁃20⁃2575.
［359］	喻靖傑, 李子晴, 何泽慧, 等. 银屑灵片及其优化方治疗寻常型银屑病的疗效及安全性的Meta分析［J］. 中药新药与临床药理, 2021,32（7）:1048⁃1054. doi: 10.19378/j.issn.1003⁃9783. 2021.07.021.
［360］	吕景晶, 韩晓丽, 孙雯雯, 等. 养血解毒汤联合中药药浴治疗血燥型银屑病临床观察［J］. 中华中医药杂志, 2021,36（7）:4405⁃4407.
［361］	兰晓鸥. 阿维A胶囊联合当归饮子加减治疗寻常型银屑病的临床疗效观察［J］. 中国现代药物应用, 2021,15（6）:230⁃232. doi: 10.14164/j.cnki.cn11⁃5581/r.2021.06.096.
［362］	李斌, 陈达灿. 中西医结合皮肤性病学［M］. 10版. 北京: 中国中医药出版社, 2017: 202.
［363］	杨彤, 刘学伟, 李建伟, 等. 复方青黛胶囊（丸）治疗寻常型银屑病的疗效及安全性Meta分析［J］. 中医药导报, 2021,27（5）:164⁃167,173.
［364］	郑雯, 李刚刚, 刘清民, 等. 复方青黛胶囊治疗寻常型银屑病疗效及安全性Meta分析［J］. 中国中西医结合皮肤性病学杂志, 2020,19（6）:540⁃545. doi: 10.3969/j.issn.1672⁃0709.2020. 06.011.
［365］	李捷, 吴晓军, 张海骄, 等. 消银颗粒联合阿维A胶囊治疗寻常型银屑病的Meta分析［J］. 西北国防医学杂志, 2021,42（3）:153⁃157. doi: 10.16021/j.cnki.1007⁃8622.2021.03.005.
［366］	蒋琴, 王起成, 邓涵杰, 等. 消银颗粒联合窄谱中波紫外线照射治疗寻常型银屑病Meta分析［J］. 河南中医, 2021,41（8）:1199⁃1205. doi: 10.16367/j.issn.1003⁃5028.2021.08.0273.
［367］	吴清, 袁丽宜, 习元堂, 等. 银屑胶囊联合阿维A胶囊治疗寻常型银屑病有效性与安全性的Meta分析［J］. 中国药房, 2019, 30（12）:1697⁃1701. doi: 10.6039/j.issn.1001⁃0408.2019.12.22.
［368］	吕萍. 克银丸联合NB⁃UVB治疗寻常性银屑病疗效观察［J］. 中国皮肤性病学杂志, 2009,23（8）:539⁃540.
［369］	王彦, 胡媚, 杨桂芝. NB⁃UVB联合百癣夏塔热片治疗寻常型银屑病疗效观察［J］. 中国麻风皮肤病杂志, 2014,30（2）:124⁃125.
［370］	左树成. 雷公藤多甙联合郁金银屑片治疗寻常型银屑病疗效观察［J］. 世界最新医学信息文摘（连续型电子期刊）, 2017,17（93）:187. doi: 10.19613/j.cnki.1671⁃3141.2017.93.148.
［371］	梁静, 郑金福, 焦庆华. 郁金银屑片联合胸腺肽治疗银屑病156例［J］. 中国药业, 2006,15（20）:55⁃55. doi: 10.3969/j.issn. 1006⁃4931.2006.20.039.
［372］	丁文, 赵西博. 紫丹银屑胶囊联合窄谱中波紫外线治疗寻常型银屑病疗效及对VEGF水平、PASI评分的影响［J］. 中国中西医结合皮肤性病学杂志, 2019,18（6）:592⁃595. doi: 10. 3969/j.issn.1672⁃0709.2019.06.020.
［373］	Lv M, Deng J, Tang N, et al. Efficacy and safety of Tripterygium Wilfordii Hook F on psoriasis vulgaris: a systematic review and meta⁃analysis of randomized controlled trials［J］. Evid Based Complement Alternat Med, 2018,2018:2623085. doi: 10.1155/2018/2623085.
［374］	Yu JJ, Zhang CS, Coyle ME, et al. Compound glycyrrhizin plus conventional therapy for psoriasis vulgaris: a systematic review and meta⁃analysis of randomized controlled trials［J］. Curr Med Res Opin, 2017,33（2）:279⁃287. doi: 10.1080/03007995.2016. 1254605.
［375］	Zheng Q, Jiang W, Sun X, et al. Total glucosides of paeony for the treatment of psoriasis: a systematic review and meta⁃analysis of randomized controlled trials［J］. Phytomedicine, 2019,62:152940. doi: 10.1016/j.phymed.2019.152940.
［376］	Yu JJ, Zhang CS, Zhang AL, et al. Add⁃on effect of chinese herbal medicine bath to phototherapy for psoriasis vulgaris: a systematic review［J］. Evid Based Complement Alternat Med, 2013,2013:673078. doi: 10.1155/2013/673078.
［377］	蔺依, 李迅, 屈双擎, 等. 中药熏蒸治疗寻常型银屑病疗效及安全性的系统评价［J］. 北京中医药, 2021,40（9）:1028⁃1032. doi: 10.16025/j.1674⁃1307.2021.09.026.
［378］	中国中西医结合学会皮肤性病学专业委员会特色疗法学组. 寻常型银屑病中医外治特色疗法专家共识（2017年）［J］. 中国中西医结合皮肤性病学杂志, 2017,16（6）:547⁃550. doi: 10.3969/j.issn.1672⁃0709.2017.06.027.
［379］	Li N, Zhao W, Xing J, et al. Chinese herbal Pulian ointment in treating psoriasis vulgaris of blood⁃heat syndrome: a multi⁃center, double⁃blind, randomized, placebo⁃controlled trial［J］. BMC Complement Altern Med, 2017,17（1）:264. doi: 10.1186/s12906⁃017⁃1631⁃5.
［380］	龚丽萍, 黄港, 朱启婵, 等. 金黄膏联合走罐疗法治疗斑块型银屑病30例?［J］. 江西中医药大学学报, 2016,28（4）:38⁃39,45.
［381］	陈丽红, 赵文杰. 复方青黛膏治疗寻常型银屑病60例［J］. 光明中医, 2014,29（7）:1413⁃1414. doi: 10.3969/j.issn.1003⁃8914. 2014.07.028.
［382］	Lin YK, Yen HR, Wong WR, et al. Successful treatment of pediatric psoriasis with Indigo naturalis composite ointment［J］. Pediatr Dermatol, 2006,23（5）:507⁃510. doi: 10.1111/j.1525⁃1470.2006.00295.x.
［383］	孙少馨, 瞿幸, 李玲玲, 等. 紫草油走罐治疗斑块型银屑病临床研究［J］. 现代中医临床, 2016,23（1）:29⁃32. doi: 10.3969/j.issn.2095⁃6606.2016.01.007.
［384］	茅玮炜, 李峰, 赵先英, 等. 外用三草油治疗轻度寻常性银屑病的临床疗效研究［J］. 临床皮肤科杂志, 2019,48（2）:117⁃119. doi: 10.16761/j.cnki.1000⁃4963.2019.02.020.
［385］	Xing M, Yan X, Yang S, et al. Effects of moving cupping therapy for plaque psoriasis: study protocol for a randomized multicenter clinical trial［J］. Trials, 2020,21（1）:229. doi: 10. 1186/s13063⁃020⁃4155⁃0.
［386］	Coyle M, Deng J, Zhang AL, et al. Acupuncture therapies for psoriasis vulgaris: a systematic review of randomized controlled trials［J］. Forsch Komplementmed, 2015,22（2）:102⁃109. doi: 10.1159/000381225.
［387］	押丽静, 刘文静, 李锘, 等. 6穴位埋线治疗寻常型银屑病的应用进展［J］. 中国中西医结合皮肤性病学杂志, 2019,18（1）:86⁃88. doi: 10.3969/j.issn.1672⁃0709.2019.01.034.
［388］	Liu L, Sun XY, Lu Y, et al. Fire needle therapy for the treatment of psoriasis: a quantitative evidence synthesis［J］. J Altern Complement Med, 2021,27（1）:24⁃37. doi: 10.1089/acm.2019.0409.
［389］	陈朝霞, 李萍, 张广中, 等. 艾灸治疗血瘀证斑块型银屑病:随机对照研究［J］. 中国针灸, 2021,41（7）:762⁃766. doi: 10. 13703/j.0255⁃2930.20200907⁃0004.
［390］	Lu CJ, Xiang Y, Xie XL, et al. A randomized controlled single⁃blind clinical trial on 84 outpatients with psoriasis vulgaris by auricular therapy combined with optimized Yinxieling Formula［J］. Chin J Integr Med, 2012,18（3）:186⁃191. doi: 10.1007/s11655⁃012⁃1020⁃3.
［391］	Borodzicz S, Rudnicka L, Mirowska⁃Guzel D, et al. The role of epidermal sphingolipids in dermatologic diseases［J］. Lipids Health Dis, 2016,15:13. doi: 10.1186/s12944⁃016⁃0178⁃7.
［392］	Li Q, Fang H, Dang E, et al. The role of ceramides in skin homeostasis and inflammatory skin diseases［J］. J Dermatol Sci, 2020,97（1）:2⁃8. doi: 10.1016/j.jdermsci.2019.12.002.
［393］	Liu M, Li X, Chen XY, et al. Topical application of a linoleic acid⁃ceramide containing moisturizer exhibit therapeutic and preventive benefits for psoriasis vulgaris: a randomized controlled trial［J］. Dermatol Ther, 2015,28（6）:373⁃382. doi: 10.1111/dth.12259.

[1]	Jiang Xiaoyan, Gao Min, Zhang Xiaoyan, Liu Ningyuan. Interleukin-17 and interleukin-23 inhibitors in the treatment of pustular psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(7): 689-692.
[2]	Tang Zhiming, Jing Mengqing, Lu Lu, Shan Xiao, Zhang Cuixia, Zhang Xiaoyu, Meng Sa. Effect of Xidi Liangxue recipe on the proliferation and apoptosis of HaCaT cells through the lncRNA NEAT1/miR-485-5p/STAT3 regulatory network [J]. Chinese Journal of Dermatology, 2023, 56(7): 642-650.
[3]	Shan Ying, Chang Xiaotong, Zuo Yagang. Epitope spreading in autoimmune bullous diseases [J]. Chinese Journal of Dermatology, 2023, 56(7): 702-705.
[4]	Chen Qiquan, Yang Xianjie, Wang Wenwen, Liang Gaopeng, Song Zhiqiang . Development and application of clinical assessment tools for cholinergic urticaria [J]. Chinese Journal of Dermatology, 2023, 56(6): 563-566.
[5]	Mi Shuhong, Yu Yanqin, Hao Jinqi, Li Wei, Zhang Yang, Jia Ximei, Huang Yuxian, Sun Huaiyu, Shi Jihai. Analysis of imaging characteristics of papulopustular rosacea by high-frequency ultrasound combined with color Doppler flow imaging [J]. Chinese Journal of Dermatology, 2023, 56(6): 540-544.
[6]	Liang Yunsheng, Li Zhanhong, Wu Yibei. Progress in the treatment of chronic spontaneous urticaria: insights from the changes in the understanding of its pathogenesis [J]. Chinese Journal of Dermatology, 2023, 56(6): 552-558.
[7]	Yang Nali, Xu Qiuyang, Wu Hanwen, Ye Yahui, Zhu Jiling, Liu Jingjing, Li Zhiming. Efficacy and safety of omalizumab in the treatment of chronic urticaria: a retrospective analysis [J]. Chinese Journal of Dermatology, 2023, 56(6): 518-524.
[8]	Su Chang, Sui Xiuli, Liu Ruiling, Cao Yiqun, Jiang Hong, Yan Cairong, Wang Huiping, Qi Yuqing. Omalizumab for the treatment of 74 patients with chronic spontaneous urticaria accompanied by other allergic diseases: a clinical analysis [J]. Chinese Journal of Dermatology, 2023, 56(6): 512-517.
[9]	Wang Xin, Liu Lijuan, Li Linfeng. Clinical features of chronic spontaneous urticaria in China: results from a hospital-based multicenter epidemiological survey [J]. Chinese Journal of Dermatology, 2023, 56(6): 525-530.
[10]	Li Liqiao, Peng Cong, Chen Xiang, Li Jie. Efficacy of omalizumab in the treatment of chronic urticaria patients with poor response to antihistamines: a single-center retrospective study [J]. Chinese Journal of Dermatology, 2023, 56(6): 504-511.
[11]	Chen Qiquan, Yang Xianjie, Gu Heng, Xu Jinhua, Hao Fei, Yao Xu, Song Zhiqiang. Construction of “Expert consensus on diagnosis and treatment of chronic inducible urticaria in China （2023）” based on the Delphi method [J]. Chinese Journal of Dermatology, 2023, 56(6): 534-539.
[12]	Immunology Group, Chinese Society of Dermatology. Expert consensus on diagnosis and treatment of chronic inducible urticaria in China （2023） [J]. Chinese Journal of Dermatology, 2023, 56(6): 479-488.
[13]	Writing Committee Expert Group on “Treatment of mycosis fungoides: a Chinese expert consensus （）”. Treatment of mycosis fungoides: a Chinese expert consensus （2023） [J]. Chinese Journal of Dermatology, 2023, 56(5): 402-409.
[14]	Hu Qingjie, Zhou Min, Yao Xu. Analysis of clinical characteristics of 36 patients with pyoderma gangrenosum and comparison between the PARACELSUS score and Delphi criteria for their diagnosis [J]. Chinese Journal of Dermatology, 2023, 56(5): 410-414.
[15]	Committee on Sexually Transmitted Diseases, China Dermatologist Association. Expert consensus on clinical management of serofast state in syphilis （2023） [J]. Chinese Journal of Dermatology, 2023, 56(5): 383-388.

Guideline for the diagnosis and treatment of psoriasis in China （2023 edition）

PDF

Knowledge

Abstract

Cite this article

share this article

References ［393］

Related Articles 15

Metrics

Comments

Recommended 10